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INTRODUCTION
Hospital  acquired infections continue to be an important  cause of 
morbidity  and mortality  among hospitalized patients.  1,  24 The critically  ill 
patient is at particular risk of developing ICU acquired infection, with the 
lungs being especially vulnerable. 2
Hospital  acquired  pneumonia  (HAP)  is  currently  the  second most 
common hospital infection accounting for 13 to 18 percent of all nosocomial 
infections,  with  estimates  of  associated  mortality  ranging from 20  to  50 
percent. 2
The majority of cases of HAP occur outside of ICUs. However the 
highest risk is in patients on mechanical ventilation. Estimates of incidence 
range from 4 to 7 episodes per 1000 hospitalizations.  3 Intubated patients 
may have rates of pneumonia 7 to 21- fold higher than patients without a 
respiratory  therapy  device.  5 Infection  rates  are  twice  as  high  in  large 
teaching hospitals as compared with smaller institutions. 5
HAP  results  in  a  significant  increase  in  the  cost  of  care  of 
hospitalized patients.  3   Its development prolongs a patient’s stay in the 
ICU 3, 4 and most of the extra cost is due to an increased length of hospital 
stay. 3, 19
The causes  of  HAP are  varied  and  differ  across  different  patient 
populations  and  different  types  of  ICUs.  4 Hospital  acquired  bacterial 
pneumonia  is  frequently  polymicrobial  with  gram  negative  bacilli 
predominating. 5, 22   This varied presentation underscores the need for the 
intensivists treating the patients with HAP to have a clear knowledge of the 
ambient microbiological flora in their ICU.4
Delayed administration of adequate antibiotic therapy is linked to an 
increased mortality  rate.  6    Hence,  the  focus of  initial  antibiotic  therapy 
should  provide  rapid  antibiotic  coverage  for  all  likely  pathogens.  The 
antibiotic spectrum may then be focused or narrowed based on the results 
of  cultures.  A  guideline-based approach using  the  local  hospital  or  ICU 
antibiogram may help in appropriate and adequate initial therapy and hence 
reduce the overall use of antibiotics and the associated selection pressure 
for multi drug resistant organisms.6
Bacteria belonging to the genus Klebsiella frequently cause human 
nosocomial infections. In particular, the medically most important Klebsiella 
species  K.pneumoniae,  accounts  for  a  significant  proportion  of  HAP. 
Because of their ability to spread rapidly in the hospital environment, these 
bacteria tend to cause nosocomial outbreaks. Hospital outbreaks of Multi  
Drug Resistant Klebsiella species are often caused by newer type strains, 
the so called Extended Spectrum Beta lactamase (ESBL) producers. The 
incidence of ESBL producing strains among clinical Klebsiella isolates has 
been steadily increasing over the past years. 7
Epidemiological  typing  is  useful  in  determining  the  extent  of  an 
outbreak  and  in  elucidating  the  sources  and  spread  of  infection.  8 
Combination of Klebocin typing and antibiogram suggest an important tool  
for epidemiological studies. 9
Though HAP is widely analyzed by many researchers, not much is known 
about the incidence and bacteriological profile i.e., only few studies are 
being published by them. This study is conducted prospectively to evaluate 
the clinical and bacteriological profile of HAP in ICU patients. It may 
increase the awareness of clinicians about the need to reduce the morbidity 
and mortality by coming to know about the various pathogens causing HAP 
and its sensitivity and/or resistance to various antibiotics. The clinicians 
need to establish a suitable antibiotic policy by working out local ICU 
antibiogram charts. This study is also done to find out the prevalence of 
ESBL producers in HAP. Klebocin typing in association with antibiogram 
may help to find out the source of Hospital Acquired Infections.
THE OVERALL AIM OF THE STUDY:
To analyze  the  incidence,  epidemiology,  antimicrobial  susceptibility 
pattern  of  isolates  from  HAP  patients  in  IMCU  and  klebocin  typing  of 
Klebsiella pneumoniae isolated in HAP.
OBJECTIVES:
1. To  study  the  incidence  of  Hospital  Acquired  Pneumonia  (HAP) 
among patients admitted in IMCU.
2. To evaluate the Clinical and Bacteriological profile of HAP.
3. To determine the antibiotic susceptibility pattern of the all bacteria 
isolated.
4. To find out the prevalence of ESBL producers in HAP.
5. To evaluate the role of Klebocin typing in epidemiological typing of 
K.pneumoniae strains.
6. To detect  the source of  infection in  IMCU using antibiogram and 
klebocin typing.
REVIEW OF LITERATURE
            Hospital Acquired Pneumonia (HAP) or Nosocomial pneumonia is 
defined as pneumonia that occurs at least 48 hours after a patient has been 
admitted  to  the  hospital  and  that  was  not  incubating  at  the  time  of 
admission. Ventilator-  Associated Pneumonia (VAP) is a type of HAP in 
patients receiving mechanical ventilation that arises at least 48 hours after 
endo tracheal intubation. 11
Epidemiology:
          Accurate information concerning the epidemiology of HAP is lacking, 
as there is no universally accepted criteria for its diagnosis.  1   HAP is the 
second most frequent nosocomial infection. 2 In the year 2006 Glasgow et al 
reported that in United Kingdom, HAP accounted for approximately 25% of 
hospital infections and was as common as that of the UTI.  12    In various 
other  studies  conducted  by  different  authors  in  United  States HAP 
accounted for approximately 15% of all Hospital- related infections and had 
been reported as the second most common HAI next to UTI.  2, 10, 30, 31 In the 
year 2007 Muhammad et al reported that HAP accounted for 21% of all HAI 
in two medical ICUs of a public tertiary care hospital, Karachi and showed 
that HAP was the third most common HAI next to UTI (44.6%) and blood 
stream infection (27%). 22 
         
The  incidence  of  HAP  differs  in  different  Intensive  Care  Units.  22 
Factors like patient population, criteria used for diagnosis,  length of ICU 
stay  and  prior  exposure  to  antibiotics  may  influence  the  incidence  of 
HAP.1,18  According to European  Prevalence of Infection in Intensive Care 
study (EPIC) by Vincent  et al involving over 4500 patients, the incidence of 
HAP in ICU was 46.9%.  25    Chevret  et  al  from France reported in their 
multicenter  prospective  study on 996 patients  admitted in  ICUs that  the 
incidence of HAP was 8.9%. 29    Alp   et al from Netherlands reported that 
the incidence was 6.8% in ICU patients in the year 2004.  32    In US the 
incidence of HAP in ICU patient ranged between 7.8 to 68 percent.  2, 10,  31 
Sopena et al from Spain reported that the incidence of HAP was 36.4% 
during  the  year  2005.  30  Berba  et  al  from  Philadelphia  reported  that 
incidence was 28.2% among ICU patients. 33
The incidence of  HAP is  age dependent.  HAP is  most common in 
elderly  patient  aged  >60  years.  However  patients  of  any  age  may  be 
affected. No racial and  sexual predilection exists.  12,  20  Muhammad  et al 
from Karachi  in their study divided the patients admitted in ICU into six age 
groups and reported that the highest incidence was seen in patients of 41 to 
60 years of age. 22   Berba et al from Philadelphia reported that 30% of the 
patients were more than 60 years of age. 33   
HAP is the leading cause of death from infections that are acquired in 
the hospital. 2   Heyland et al from France showed that the patients with HAP 
stayed in the ICU for 4.3 days longer and had a trend toward an increase in  
risk of death.  26    Mortality rate for HAP ranges between 24 and 50%. 4, 28 
Celis et al from Spain reported that the mortality rate was 36.6% among 
HAP patients in a 1000- bed teaching hospital. 27   Sopena et al from Spain 
in  the year  2005 reported that  the mortality  rate was  26% among HAP 
patients. 30   Alp et al from Netherlands reported that the mortality rate was 
65% in ICU patients with HAP in the year 2004. 32
Time  is  an  important  epidemiological  variable  and  risk  factor  for 
specific pathogens & outcomes in patient with HAP & VAP. 11   Early-Onset 
HAP  is  defined  as  pneumonia  occurring  within  the  first  4  days  of 
hospitalization,  usually  having  a  better  prognosis.   Late-Onset  HAP  is 
defined as pneumonia occurring after five or more days of hospitalization, 
which are more likely to be caused by MDR pathogens and are associated 
with increased patient mortality & morbidity.  11
Indian scenario:
Merchant et al from Mumbai in year 1998 reported that the incidence 
of HAP among IMCU patients was 16.7% and the mortality rate was 40% in 
HAP.   19    Trivedi et  al  from Mumbai  in the year  2000 reported that  the 
incidence of HAP in IMCU was 9.38% with the mortality rate of 21.3%; in 
the  same  year  another  study  from  Mumbai  by Tullu  et  al  in  Pediatric 
Intensive  Care  Unit  showed  the  incidence  of  HAP  as  27.54% with  the 
mortality rate of 47.37%. 16, 17  
  Mukhopadhyay et al  from Lucknow in the year  2003 reported the 
incidence of HAP in ICU patients as 53.9% and the mortality rate as 47.3%. 
18      Pawar et al from New Delhi in the year 2003 reported the incidence of 
HAP as 2.6% among ICU patients with the mortality rate of 16%.  14   Rakshit 
et al   from Mumbai in the year 2005 reported the incidence as 47% and the  
mortality rate as 37%. 13     Dey et al from Manipal in the year 2007 reported 
that the incidence of HAP being 45.4%.15     
Risk factors for the development of HAP: 
There  are  several  risk  factors  for  the  development  of  HAP  like 
Mechanical ventilation, Reintubation, Age > 60 years,  Severity of illness, 
Acute or chronic lung disease, Excessive sedation, Enteral nutrition, Supine 
body  positions,  Glasgow  coma  scale  <  9,  Use  of  Muscle  relaxants, 
Cigarette  smoking,  Administration  of  antacids  or  histamine  type  2 
antagonists,  Emergency surgery,  Prior Antibiotic use, Duration of ICU or 
Hospital stay. 1, 21, 37
Intubation and mechanical ventilation increase the risk of HAP from 6- 
to 21- fold and up to 28% of patients receiving mechanical ventilation will  
develop  this  complication.  1 Many  studies  on  HAP  showed  that  the 
occurrence of HAP was high in the ICUs mainly because of high utilization 
of  invasive  procedures  like  mechanical  ventilation.  36    Rakshit  et  al 
reported  that  the  significant  risk  factors  for  development  of  HAP  were 
prolonged duration of mechanical ventilation, higher APACHE III scores on 
admission signifying severe illness and reintubation. 13   Mukhopadhyay et 
al from Lucknow in the year 2003 reported unplanned or failed extubation 
followed by re-intubation as a significant risk factor for the development of 
pneumonia.  It  is  probable  that  aspiration  of  infected  upper  airway 
secretions occurs at the time of reintubation. Dey et al from Manipal in the 
year  2007  reported  that  reintubation  was  a  definitive  risk  factor  for  the 
development of HAP. 15 
Pawar  et  al  reported  that  the  risk  factors  for  HAP  were  COPD, 
emergency surgery, reintubation, coma, steroid treatment, enteral feedings 
and prior antibiotics in their study.  14  Stress ulcer prophylaxis is routinely 
used in the critically ill. The use of H2 blockers is associated with a change 
in  the acidity  of  the gastric  juices that  favors  bacterial  colonization with 
Gram negative bacteria.  33 
Celis et al reported that factors significantly predisposing to HAP were 
tracheal intubations, depressed level of consciousness, underlying chronic 
lung diseases, thoracic or upper abdominal surgery and age older than 70 
years.   27    Enteral  feeding  via  a  nasogastric  tube  promotes  gastro-
esophageal reflux and is also associated with an increase in gastric pH and 
colonization  of  the  stomach  with  aerobic  Gram  negative  bacilli.  33 
Mukhopadhyay et al reported in their study that the rate of acquisition of 
HAP increased along with the duration of stay in the ICU. 18
Pathogenesis of HAP: 
  For HAP to occur, the delicate balance between host defenses and 
microbial propensity for colonization and invasion must shift in favor of the 
ability of the pathogens to persist and invade the lower respiratory tract.
Sources  of  pathogens  for  HAP  include  healthcare  devices,  the 
environment  (Air,  water,  equipment,  and  fomites),  and  can  occur  with 
transfer of microorganisms between the patient and staff or other patient. A 
number of host-  and treatment-  related colonization factors,  such as the 
severity  of  the  patient’s  underlying  disease,  prior  surgery,  exposure  to 
antibiotics, other medication and exposure to invasive respiratory devices 
and equipment are important in the pathogenesis of HAP and VAP. 11
 Inhalation, aspiration and hematogenous spread are the three main 
mechanisms  by  which  pathogens  reach  the  lungs.  Inhalation  or  direct 
inoculation of pathogens into the lower airway, hematogenous spread from 
infected  intravenous  catheters,  and  bacterial  translocation  from the  GIT 
lumen  are  uncommon  pathogenic  mechanisms. 
Aspiration of oropharyngeal pathogens or leakage of secretions containing 
bacteria around the endotracheal tube cuff is the primary routes of bacterial 
entry into the LRT. 20
 Infected  biofilm  in  the  endotracheal  tube,  with  subsequent 
embolization to distal airways, may be important in the pathogenesis of VAP. 
The  stomach  and  sinuses  may  be  potential  reservoirs  of  nosocomial 
pathogens  that  contribute  to  bacterial  colonization  of  the  oropharynx,  but 
their contribution is controversial which may vary by the population at risk, 
and may be decreasing with the changing natural history and management of 
HAP. 11, 20
Microbiology of HAP: 
           HAP is caused by a wide spectrum of bacterial pathogens, may be 
polymicrobial  and  rarely  due  to  viral  or  fungal  pathogens.  Common 
pathogens  include  aerobic  gram-negative  bacilli  such  as  P.aeruginosa, 
Klebsiella  pneumoniae,  Escherichia  coli,  Acinetobacter  species, 
Streptococcus  pneumoniae  and  Haemophilus  influenzae.  Serratia, 
Legionella pneumophila , Stenotrophomonas maltophilia and Burkholderia 
cepacia are uncommon bacteria causing HAP. 
Fungal  pathogens  isolated  from  HAP  are  Candida  species  and 
Aspergillus fumigatus. Influenza, Para influenza, Adenovirus, Measles and 
Respiratory Syncytial Virus are viral pathogens causing HAP.  11, 20      The 
bacteriology  of  nonventilated  patients  was  similar  to  that  of  ventilated 
patients,  including infection with  pathogens such as  methicillin-  resistant 
Staphylococcus aureus (MRSA), P.aeruginosa, Acinetobacter species and 
K.pneumoniae.11
Chastre  et  al  from  Paris  in  the  year  2002  reported  that  the 
predominant organisms responsible for HAP being Staphylococcus aureus, 
Pseudomonas aeruginosa and Enterobacteriaceae. 28 
Leroy  et  al  from France in  the  year  2002 reported  that  the  main 
organisms  were  P.aeruginosa  (31.2%),  Enterobacteriaceae  (20.8%), 
Staphylococcus  aureus  (18.8%)  with  33%  Methicillin-  resistant  strain, 
Haemophilus  influenzae  (6.5%),  Streptococcus  pneumoniae  (5.8%), 
Acinetobacter spp. (5.8%) and Stenotrophomonas maltophilia (5.2%). 35 
Alp et  al  from Netherlands in  the year  2004 studied that  the most 
commonly  isolated  pathogens  were  Acinetobacter  baumanii  (29.6%),  P. 
aeruginosa  (20.6%)  and  Klebsiella  pneumoniae  (14.4%)  among  HAP 
patients. 32   
Tullu  et al from Mumbai in the year 2000 studied the bacteriology of 
HAP  in  Pediatric  Intensive  Care  Unit  and  reported  that  the  organisms 
commonly isolated being E. coli (34.4%), Klebsiella pneumoniae (30.2%), 
Pseudomonas (11.5%), Proteus (11.5%) and Acinetobacter (5.2%). 17 
Mukhopadhyay   et  al  from Sanjay  Gandhi  Post  Graduate  Institute 
Medical Sciences, Lucknow, in the year 2002 reported that Gram negative 
organisms  were  isolated  more  frequently  than  Gram  positive  cocci  in 
patients with HAP; Pseudomonas aeruginosa was the most frequent isolate 
followed by E.coli and Klebsiella pneumoniae. 18   
Pawar  et al in the year 2003 from New Delhi reported that the most 
common  pathogens  isolated  from  HAP  cases  being  Pseudomonas 
aeruginosa,  E.coli,   Klebsiella  pneumoniae,  Staphylococcus species and 
Acinetobacter species in that order. 14  
 Rakshit  et  al  from Mumbai  reported  that  most  common offending 
organism  isolated  in  cases  with  VAP  was  P.aeruginosa  followed  by 
Klebsiella and E. coli in the year 2005. 13  
Rajasekhar  et  al  from  Nizam’s  Institute  of  Medical  Sciences, 
Hyderabad,  in  the  year  2006  reported  that  Acinetobacter  baumanii  and 
Klebsiella pneumoniae were commonest isolates among HAP patients. 23   
Dey  and  Bairy  in  the  year  2007  from  Manipal  reported  that 
Acinetobacter species (48.94%) was the commonest organism followed by 
Pseudomonas aeruginosa (25.53%), Klebsiella pneumoniae (12.77%), E. 
coli (10.64%) and Serratia marcescens (2.13%).15
 Klebsiella pneumoniae – An important pathogen in HAP:
The Genus Klebsiella is defined as containing gram-negative, non-
motile, usually encapsulated rod-shaped, lactose fermenting bacteria of the 
family  Enterobacteriaceae  which  produce  lysine  decarboxylase  but  not 
ornithine decarboxylase and are generally positive in the Voges-Proskauer 
test.
Epidemiology:
          Klebsiella species are ubiquitous in nature.  The two common 
habitats of Klebsiella are the environment such as surface water, sewage, 
soil  &  plants  and  the  mucosal  surfaces  of  mammals  such  as  humans, 
horses  or  swine.  In  humans  Klebsiella  pneumoniae  is  present  as  a 
commensal in the nasopharynx with carrier rate ranging between 1 and 6% 
and  in  the  intestinal  tract  with  the  detection  rate  in  the  stool  samples 
ranging from 5 to 38%.  It is rarely found on the human skin. 7
         In the hospital  environment colonization rates increase in direct 
proportion to  the length of  stay.  Tulsi  et  al  reported that  colonization of 
intestine,  umbilical  stump,  throat,  skin  and  external  ear  with  Klebsiella 
pneumoniae increased from 10 percent on admission to 26 percent on day 
3 and 39 percent on day 6 in a Neonatal Intensive Care Unit.  69    Reported 
carrier rates in hospitalized patients are 77% in stool, 19% in pharynx and 
42% on the hands of patients.
 The  significance  of  increased  colonization  was  illustrated  by  the 
observation that the attack rate of Klebsiella nosocomial infection in patients 
having  colonization  of  Klebsiella  was  four  times as  high  as  for  patients 
without  colonization.  7    Even hospital  personnel  have  elevated rates  of 
Klebsiella colonization.   The principal reservoirs of K. pneumoniae in the 
hospital setting are medical equipment (contaminated due to faulty hygienic 
procedures),  blood products,  GIT of  patients and hands and pharynx of 
hospital personnel. 7
Incidence of Klebsiella pneumoniae in HAI:
As an opportunistic pathogen, K.pneumoniae primarily attack immuno 
compromised  individuals  who  are  hospitalized  and  suffer  from  severe 
underlying diseases such as DM or COPD. 7    Table 1 show the percentage 
of Hospital acquired Infections caused by Klebsiella pneumoniae and the 
rank of Klebsiella pneumoniae compared to all other bacterial pathogens. 
Table 1.HAI caused by K.pneumoniae: 7
Infection %  of  infections 
caused  by 
Klebsiella
Rank (Compared  to 
all  other  bacterial 
pathogens)
UTI 6 – 17 5 – 7
Pneumonia 7 – 14 2 – 4
Septicemia 4 – 15 3 – 8
Wound infections 2 – 4 6 – 11
Nosocomial infections 
in ICU patients 
4 – 17 4 – 9
Neonatal septicemia 3 – 20 2 – 8
Lockhart S R et al  from Chicago reported that during their 12-year 
study period  from 1993  to  2004,  74,394 gram-negative  bacillus  isolates 
recovered from intensive care unit (ICU) patients in United States hospitals 
and Klebsiella pneumoniae accounted for 14.2% of the total HAI.  76    Aly et 
al from Egypt   in the year 2008 reported that the incidence of Klebsiella 
pneumoniae in nosocomial infections in a medical – surgical Intensive Care 
Unit was 11%. 77     
Gaynes   et   al and the National Nosocomial Infections Surveillance 
System  (NNISS),  Centers  for  Disease  Control  and  Prevention,  Atlanta 
reported in the year 2005 that the incidence of Klebsiella pneumoniae in 
nosocomial pneumonia was 8.4%, in urinary tract infection 4.6%, in blood 
stream infection 4.5% and in surgical site infection 2.7%. 78   Muhammad in 
the  year  2007  from  Karachi  reported  that  the  incidence  Klebsiella 
pneumoniae in nosocomial infections in Intensive Care Unit was 17.4%. 22 
Pal R B et al from Mumbai reported that Klebsiella pneumoniae accounted 
for 26.66% of nosocomial infections in Intensive Care Unit. 9
Incidence of Klebsiella pneumoniae in HAP:
              In most of the studies, K.pneumoniae was the second most  
common pathogen causing HAP next to P.aeruginosa.  Merchant et al from 
Mumbai in year 1998 reported that the incidence of Klebsiella pneumoniae 
in  HAP  among  IMCU  patients  was  34%  and  it  was  the  second  most 
common pathogen next to P. aeruginosa (44%).  19   
Tullu et al from Mumbai in the year 2000 in their study of bacteriology 
of HAP in Pediatric Intensive Care Unit reported the incidence of Klebsiella 
pneumoniae as 30.2%. 17   
Mukhopadhyay et al Sanjay Gandhi Post Graduate Institute Medical 
Sciences, Lucknow, in the year 2002 reported that Klebsiella pneumoniae 
had been isolated as a pathogen from 16.8% of HAP patients.18     
Pawar  et  al  in  the  year  2003  from  New  Delhi  reported  that  the 
incidence of Klebsiella pneumoniae was 9.5% among HAP patients. 14  
  Rakshit  et  al  from  Mumbai  in  the  year  2005  reported  that  the 
incidence  of  Klebsiella  pneumoniae  in  VAP was  21.8% and  it  was  the 
second most common pathogen next to P.aeruginosa. 13   
 Dey and Bairy in the year 2007 from Manipal reported that 12.77% of 
HAP was caused by Klebsiella pneumoniae.  15   
Rajasekhar  et  al  from  Nizam’s  Institute  of  Medical  Sciences, 
Hyderabad,  in  the year  2006 reported Klebsiella  pneumoniae accounted 
18.18% of total isolates among HAP patients. 23
 
 Pathogenicity Factors of Klebsiella: 7
 1. Capsular Antigens:
   The capsular repeating subunits consisting of four to six sugars and 
very  often  uronic  acids  (as  negatively  charged  components)  can  be 
classified  into  77  serological  types.  The  capsular  material  forms  thick 
bundles of fibrillous structures covering the bacterial  surface in  massive 
layers.  This  protects  the  bacterium  from  phagocytosis  by 
polymorphonuclear  granulocytes  and  prevents  killing  of  the  bacteria  by 
bactericidal serum factors. The molecular mechanism presumably consists 
of inhibiting the activation or uptake of complement components, especially 
C3b.     
2. Pili (Fimbriae):
           These are nonflagellar, filamentous projections on the bacterial  
surface which are up to 10µm long and have a diameter of 1 to11 nm. They 
consist of polymeric globular protein subunits (pilin) with a molecular mass 
of 15 to 26 kDa. 
Type1 (common)   pili: 
This  adhesin  is  designated  as  mannose-sensitive  hemagglutinin 
(MSHA), located on the fimbrial shaft. The role of these pili is mainly for  
binding of  the  bacteria  to  mucus or  to  epithelial  cells  of  the  urogenital, 
respiratory  and  intestinal  tracts.  Adherence  of  bacteria  to  cells  of  the 
repiratory tract leads to impairment of colonization resistance in the upper 
airways with a subsequent proliferation of facultative pathogenic bacteria. 
This impairment may result in the development of pneumonia especially in 
patients undergoing long-term mechanical ventilation.
Type  3  pili: mannose-resistant,  Klebsiella-like  hemagglutinin  (MR/K-
HA).Strains of K.pneumoniae expressing type 3 pili adhere to endothelial 
cells, epithelia of the respiratory tract and uroepithelieal cells.
Other types of pili are KPF-28 Fimbria which has been found in the majority 
of     K.pneumoniae strains producing CAZ-5/SHV-4 type ESBL,  CF29K 
(Non  Fimbrial)  adhesin  belonging  to  the  K88  adhesin  family  and 
Aggregative adhesin composed of capsule-like extra cellular material.  
3. Serum Resistance and Lipopolysaccharide:
     Capsular polysaccharides (CPS) may cover and mask the underlying LPS 
and exhibit a surface structure that does not activate complement. The O 
side  chains  of  the  LPS  may  reach  through  the  capsule  layer  and  be 
exposed to the exterior milieu. C 3b is subsequently deposited onto LPS 
molecules. Since it is fixed preferentially to the longest O-polysaccharide 
side chains, C3b is far away from the bacterial cell membrane. Thus the 
formation of the lytic membrane attack complex (C5b-C9) is prevented and 
subsequent membrane damage and cell death do not take place.
4. Siderophores:
             These are high-affinity, low-molecular-weight iron chelators that are  
capable  of  competitively  taking  up  iron  bound  to  host  proteins.  Two 
different chemical groups of siderophores are Phenolate-type siderophores: 
Enterobactin  (also  known  as  enterochelin)  and  Hydroxamate-type 
siderophores: Aerobactin.
           Although the production of cytotoxins, enterotoxins and hemolysin has 
been  described,  these  features  probably  play  a  rather  minor  role  in 
Klebsiella.
Epidemiological typing of Klebsiella:
        From an epidemiological point of view it is often necessary to  
determine the clonality of the strains. A useful and effective typing system 
should be (1) standardized, (2) reproducible, (3) sensitive, (4) stable, (5) 
available,  (6)  inexpensive  and  (7)  field  tested  in  conjunction  with 
epidemiologic investigation. This is very useful  in endemic and epidemic 
nosocomial outbreaks of Klebsiella infections to improve the management 
of  such  outbreaks.  Klebsiella  marker  systems  include  determination  of 
antibiotic  susceptibility  patterns,  biotype,  serotype,  bacteriophage 
susceptibility,  Bacteriocin  susceptibility,  and  plasmid  content,  size  and 
endonuclease fragment size.  47, 48, 50  
Biotyping:
         Biotyping based on an extended panel of biochemical and culture 
test is certainly the most practicable method of typing for laboratories that 
are epidemiologically not optimally equipped.  Biotyping can be carried out  
by using macro tube tests alone or by combining a commercially available 
miniaturized system such as the API 20E system with additional macro tube 
tests.  The  drawbacks  of  this  typing  method  are  the  large  number  of 
reactions to be tested, the often long cultivation times, poor reproducibility 
and poor sensitivity.  Therefore biotyping of Klebsiella species is not very 
suitable as an epidemiological tool. 7, 47
Serotyping:
          Of 82 capsule antigens described, 77 types form the basis for an 
internationally recognized capsule antigen scheme. Capsule typing shows 
good reproducibility and is capable of differentiating most clinical isolates. 7 
The drawbacks of this method are the large number of serological cross-
reactions that occur among the 77 capsule types, the serotyping procedure 
is  cumbersome  because  of  the  time  needed  to  perform  the  test,  it  is 
susceptible to subjective interpretations because of weak reactions that are 
not  always  easy  to  interpret,  since  anti-capsule  antisera  are  not 
commercially  available,  this  technique  is  practiced  mostly  in  specialized 
laboratories. 7, 49
Although 12 different  O-antigen types of  Klebsiella  have also been 
described,  they  are  difficult  to  classify  because  their  determination  is 
hampered by the heat-stable capsules. 7  
Phage Typing:
        The phage reaction is easily read and the reproducibility of the 
method is acceptable.  This technique shows a relatively poor typing rate of 
19 to 67% and as a single typing method phage typing is not very sensitive. 
7, 47
Bacteriocin typing:
           Bacteriocins are bactericidal substances usually proteins 
produced  by  bacteria  to  inhibit  the  growth  of  other  bacteria  usually 
members of the same species.  63   In year 1988 James from UK reported 
that klebocin production was encoded by a 5.5 kb plasmid and SDS- PAGE 
klebocin gave rise to two polypeptides, one of 85 kDa and the other of 11 
kDa.  56   An  isolate  can  be  characterized  either  by  its  ability  to  inhibit  
specific indicator strains or by its sensitivity to bacteriocins synthesized by a 
set of producer strains.  Since the synthesis of bacteriocins is not frequent 
enough in Klebsiella, the latter technique has become the method of choice 
for Bacteriocin typing of organisms belonging to this genus.  This method 
has  proven  superior  for  typing  of  clinical  and  environmental  Klebsiella 
strains as well as of nosocomial outbreaks of Klebsiella. 45, 57
Bacteriocin susceptibility typing is easier and cheaper. Depending on 
the producer strains used, between 67% and 96% of strains are typable.  47 
Israil in year 1981 reported that klebocin typing was a quite simple, reliable 
method and did not imply any special requirements. The number of strains 
typable was higher than of those typable by phages and the typability was 
85% in his study.  46      The same author in year  1980 reported that the 
typability was 88.9%.  52   Podschun and Ullman in the year 1996 studied 
that 96% of strains were typable by klebocin typing. 58   They developed the 
modification of the scrape and point method for klebocin typing. 53  
 Hall used a set of 10 klebocin producing strains to type 630 clinical 
isolates of Klebsiella. The typability was 77% by streak and point method. A 
major  problem in  his  study  was  the  lack  of  reproducibility  among large 
numbers of weak reactions encountered. 59     Bauerfeind et al showed that 
the typability was 96.3% using streak and point method. 62     Buffenmyer et 
al  in  the  year  1976  developed  standard  procedures  for  the  klebocin 
production,  storage,  klebocin  titration  and the  utilization  of  klebocins  for 
typing and reported that the typability was 67% in their study. 61     
In the year 1997 Pal et al from Mumbai reported that the typability was 
71.62% using six producer strains by spot inoculation method. In view of 
the high induction of klebocins by mitomycin C, storage stability at -20 o  C 
and the simplicity of the technique, they stated spot inoculation method as 
more appropriate typing method. 9 
Chhibber et al from Panjab University, Chandigarh in the year 1998 
reported  that  by  using  six  klebocin  producer  strains  the  typability  was 
72.8%. 60    They studied the effect of various inducing agents on klebocin 
production by Klebsiella pneumoniae. A significant  level  of  klebocin was 
detected only after induction. The highest level of klebocin was achieved 
with mitomycin C followed by rifampicin and polymyxin B.  54    They also 
purified and characterized the klebocin and reported that chemical analysis 
of the purified preparation showed it to be a protein and was sensitive to 
digestion by various proteolytic enzymes. 55            
Malik et al from Aligarh Muslim University in the year 2003 reported 
that  the  typability  of  klebocin  typing  was  83.3% and reproducibility  was 
73.3%. 43    Aggarwal et al in year 2003 from Government Medical College, 
Amritsar reported that klebocin typability in their study was 73.5%. 44 
Molecular typing methods:
The procedures like plasmid profiles,  ribotyping,  multilocus enzyme 
analysis  by  polyacrylamide  gel  electrophoresis  and  pulsed-field  gel 
electrophoresis which are technically more complicated, vary from laboratory 
to laboratory and lack standardization making it difficult to compare them. 7, 47
   ESBL producing Klebsiella pneumoniae:
                 Especially feared are epidemic hospital infections caused by  
multi drug resistant strains. In the 1970s, these strains were chiefly amino 
glycoside-resistant  Klebsiella  strains.  Since  1982  strains  that  produce 
ESBLs which render them resistant to extended-spectrum cephalosporins 
have evolved. 7 Today ESBL producing Klebsiella strains are emerging and 
spreading in the community as well as hospital settings. 41 In Europe the β-
lactamases of ceftazidime-resistant Klebsiella strains are commonly of the 
SHV-type whereas TEM-10 and TEM-12 are more prevalent in the United 
States. 7
Feizabadi  et  al  reported  that  production  of  ESBL  was  detected  in 
72.8% of nosocomial Klebsiella pneumoniae isolates during their study from 
2006 to 2007 in Tehran hospitals. 74   
 Gonlugur et al in the year 2004 Turkish University Hospital reported 
that  the  incidence  of  ESBL  producing  Klebsiella  pneumoniae  among 
respiratory isolates was 12.2%. 39 
    Hosoglu et al in the year 2007 reported that 68.3% of Klebsiella 
pneumoniae  isolates  in  Turkish  hospitals  were  detected  as  ESBL 
producers. 72     
Asian HAP working group in 2008 reported the overall  incidence of 
ESBL producing Klebsiella pneumoniae as 0.9 to 40% of cases of HAP. 80  
Verhamme et al in the year 2007 from Netherlands reported that the 
incidence of ESBL producing Klebsiella pneumoniae was highest in Late- 
onset HAP (100%). 79     In the year 2007 Vitkauskiene  et al reported that the 
incidence of ESBL producing Klebsiella pneumoniae among HAP patients 
was 88.9%. 84  
Indian studies on ESBL producing Klebsiella pneumoniae: 
In India, ESBL producing strains of K.pneumoniae have emerged as a 
challenge in hospitalized as well  as community based patients.  65     High 
prevalence  of  ESBL  producing  Klebsiella  strains  has  been  reported  by 
various  groups.  In  1997,  from  Nagpur  17  out  of  66  Klebsiella  isolates 
showed  ESBL  production.  86    In  the  year  2002,  68  percent  of  Gram 
negative bacteria were found to ESBL producers in a study from New Delhi 
in which 80 percent of Klebsiella were ESBL producers. 87   
In 2004 two other studies from Delhi showed 70.6 and 12.6 percent 
Klebsiella isolates to be ESBL producers respectively. 88, 89   
 In  Lucknow the  ESBL production  were  seen in  58% of  Klebsiella 
isolates from neonatal septicemia during 2004-2005.  64  Dey and Bairy in 
the year 2007 from Manipal reported that 100 percent of K. pneumoniae 
isolates from VAP cases were ESBL producers. 15
Source detection in Hospital Acquired Klebsiella infections:
In the year 1997 Pal et al from Mumbai reported that by combination 
of klebocin types and antibiogram of clinical isolates, the source of infection 
could be traced in 86.84% cases. The sources of infection were ICU sites 
and staff in 60.52% cases, 6.31% cases as endogenous flora and rest was 
unknown. 9    
 Malik  et  al  in  the  year  2003  reported  that  Klebocin  typing  and 
antibiogram of the environmental isolates of Klebsiella pneumoniae showed 
the same pattern as was observed in patient isolates and concluded these 
isolates as the source of infection. 43     Cooke et al reported that the sources 
of  Klebsiella  infections  in  hospital  patients  could  be  found  out  using 
Serotyping and bacteriocin typing.  51      Tulsi et al detected the source of 
Klebsiella pneumoniae from ward environments using klebocin typing. 69
Clinical outcome of HAP:
Rakshit et al from Mumbai in the year 2005 reported that 37% of HAP 
patients succumbed while being treated in Medical Critical Care Unit. Five 
patients were more than 60 years old and none of them could survive. The 
mortality was significantly higher in older age group and in patients with co 
morbid illnesses.  Significantly higher survival  rates were found in cases 
that  had early and planned tracheostomy,  as compared with  those who 
needed  reintubations.  13    Trivedi et  al  from  Mumbai  in  the  year  2000 
reported  that  high  mortality  was  associated  with  habits  like  smoking 
(33.3%), age group over 60 years (27.3%), presence of comorbid illness 
like DM and COPD (38.5%), complications like ARDS (61.3%) or sepsis 
with  end  organ  failure  (73.7%)  and  need  of  intubation  (36.2%)  or 
mechanical ventilation (40.55). 16  
  Rajasekhar et al from Hyderabad in the year 2006 reported that the 
clinical condition of 87% cases in Early onset HAP and 33% cases in Late 
onset HAP improved significantly with the modification of antibiotic therapy 
made after the results of cultures of ETA samples. The over all mortality in  
their study was 18%.  23      Berba R et al in their study showed that the mean 
duration of hospitalization was almost doubled when HAP occurred. The 
mortality rates were more than three times higher among HAP patients than 
among non -HAP patients. 35% of deaths among HAP patients occurred 
within 48 hours from the time the HAP diagnosis was made. 33      
MATERIALS & METHODS
This  prospective  study  was  conducted  over  a  period  of  one  year 
among  patients  admitted  in  Intensive  Medical  Care  Unit  (IMCU)  of 
Coimbatore Medical College & Hospital, Tamil Nadu. The study population 
comprised all patients admitted to the IMCU from May 1, 2007 to April 30, 
2008.  Approval  was  obtained  from  the  Ethical  Committee  prior  to 
conducting the study and informed consent from all patients under study 
was also obtained. 
HAP was diagnosed based on standard diagnostic criteria adapted by 
the  Centers  for  Disease  Control  and  Prevention  for  the  diagnosis  of 
pneumonia if signs of pneumonia occurred after 48 hours following IMCU 
admission.  34    HAP  was  considered  when  new  or  progressive  chest 
radiographical  infiltrates  occurred  ≥48  hours  after  hospital  admission  in 
conjunction with the following clinical criteria: 
At least one of the following:
  1.  Fever (> 38° C/ 100.4° F) with no other recognized cause  
  2.  Leukocytosis  (≥  12,000  WBC/mm3)  or  leucopenia  (<  4,000  WBC/ 
mm3)
3. For  adults  ≥  70  years  old,  altered  mental  status  with  no  other 
recognized cause
4.
And    
At least two of the following:
1. New  onset  of  purulent  sputum  /  change  in  the  character  of  the 
sputum  /  increased  respiratory  secretions  /  increased  suctioning 
requirements.
2.  New  Onset  or  worsening  cough  /  dyspnea   /   tachypnea 
(Respiratory Rate > 25 breaths / min)
3. Rales or bronchial breath sounds
4. Worsening gas exchange : O2   desaturations [Pa O2 / Fi O2  ≤ 240 ] / 
increased O2 requirements / increased ventilation demand
The following cases were excluded from the study:
1. Patients who died within 48 hours from the time of admission to the 
IMCU
2. Patients discharged  or went home against medical advice within 48 
hours of admission
3. Patients who were diagnosed to have pneumonia during the time of or 
within  48  hours  of  admission  (Pneumonia  in  these  cases  were 
presumed to have developed from a previous hospital admission or 
community) 
Data collection:
Data collection began from the time of admission to the IMCU and 
continued  until  the  occurrence  of  HAP,  death  or  discharge  from  IMCU 
whichever occurred first. 
On  IMCU admission  name,  age,  sex,  address,  date  of  admission, 
diagnosis  on  admission,  underlying  illness,  presence  of  immuno 
compromised state (DM, Malignancies and AIDS), history of smoking and 
alcoholism were recorded. A thorough general & systemic examination of 
the patient was also done.
 When HAP occurred,  the time of  onset  from hospital  admission, 
temperature, chest radio graphical involvement and leukocyte count were 
recorded. Intervention – related variables including need for supplemented 
O2 & device used, need for mechanical ventilation, suctioning devices used, 
naso gastric tube placement, stress ulcer prophylaxis, steroids, sedatives 
and antibiotics actually given for    at least 48 hrs were also recorded.  
The data on the hospitalization outcome including length of hospital 
stay and discharged versus mortality was also determined.
Specimens collected:
Sputum
Bronchoscopic aspirate (BAL)
Endotracheal aspirate (ETA)
Blood
For source detection:
Swabs from the patient’s environment (i.e. IMCU sites such 
as wall, floor, trolley, suction tubing, bed & curtains) as well as swabs from 
the IMCU staff members (i.e. skin, nasal & throat swabs) were collected 
monthly.
Specimen collection & Transport:
Collection of Sputum:
The patient was instructed to rinse mouth with water before collecting 
sputum sample. Early morning sputum samples were collected in sterile 
wide mouthed containers fitted with screw capped lids.
Collection of BAL: 1, 35
A trained respiratory therapist collected the specimen every time. The 
tip of the flexible Fibre Optic Bronchoscope (FOB) was positioned close to 
the segmental area corresponding to radiographic infiltrates. Three aliquots 
of 50 ml sterile 0.9% Normal saline were instilled. After the injection of each 
aliquot,  gentle  aspiration  was  done  through  the  suction  channel.  The 
aspirates  pooled  in  a  sterile  container  were  submitted  to  the  laboratory 
immediately for microscopy & microbiological analysis.
Collection of ETA: 15
The  ETA  was  collected  using  a  22-inch   Ramson’s  12F  suction 
catheter with a mucous extractor, which was gently introduced through the 
ET tube for a distance of approximately 25-26 cm. Gentle aspiration was 
then performed without  instilling  saline and the catheter was withdrawn 
from the ET tube. After the catheter was withdrawn, 2ml of sterile 0.9% 
Normal saline was injected into it with a sterile syringe to flush the exudates 
into a sterile container for collection. ETA samples were immediately taken 
to the laboratory for processing.
Collection of Blood sample:  
After  cleansing  the  site  for  venepuncture  with  Betadine  and  70% 
Alcohol,  about  5ml of  Blood was collected and added to 50ml  of  sterile 
Brain Heart Infusion (BHI) broth in Blood culture bottles. All the specimens 
were sent to the laboratory immediately after collection. 
Collection of swabs from IMCU sites:
Swabs were collected during the time of infection from IMCU sites and 
staff. Moistened cotton wool swabs were used for collecting samples from 
the wall,  floor and trolley.  The swabs were placed in Nutrient Broth and 
incubated at 37o C overnight. After sub culturing on plates, the isolates were 
identified by standard laboratory techniques. The samples from bed clothes 
and  curtains  were  collected  by  sweep  plate  method.  The  Petri  dish 
containing culture medium was removed from its lid and rubbed over the 
fabrics. The colonies were identified after incubation by standard laboratory 
techniques.
Safety precautions:
• All  samples  were  considered  potentially  infectious  and  leak  proof 
containers were used for collection and transportation of the samples.
• Biological  safety  cabinet  class  II  was  used  for  carrying  out  all 
procedures and protective wears like mask, gloves etc was used.
• Disinfection  of  the  containers  by  treating  with  2.5%  Sodium 
Hypochlorite solution / autoclaving was followed.
Processing of specimens:
Direct Microscopy:
The BAL, ETA and sputum samples were subjected to Gram staining 
and  Potassium  Hydroxide  (KOH)  mount  using  standard  laboratory 
techniques 66, 68 to assess the quality of the samples for further processing.
Culture Procedures:
The  samples  were  mechanically  liquefied  and  homogenized  by 
vortexing for 1 min and then serially diluted in 0.9% sterile saline solution 
with final dilutions of 10-2, 10-3 and 10-4. The diluted samples were inoculated 
onto Blood Agar plate (BAP) with 10% sheep blood, Chocolate Agar plate 
with 10% sheep blood (CAP) and Mac Conkey Agar plate and Sabourauds 
Dextrose Agar plate (SDA) by using 4mm Nichrome wire loop (Himedia, 
Mumbai) which holds  0.01ml of solution for quantitative culture. 
All plates were incubated overnight at 37° C and CAP at 37° C with 
5% CO2 and one SDA plate was kept at room temperature. 
All plates were checked for growth overnight and then after 24 & 48 
hrs of incubation. SDA plates were checked for any growth daily for the first 
week and twice a week up to four week. Growth of any bacterial isolate 
below the threshold (Table 2) was assumed to be due to colonization or 
contamination.  All  the  bacterial  pathogens  with  colony  count  above  the 
diagnostic threshold were identified by colony morphology, microscopy and 
detailed biochemical testings using standard laboratory techniques. 42, 66
Table2.  Criteria  for  the  assessment  of  a  good  quality  respiratory 
sample in HAP.  35, 67 
ETA BAL SPUTUM
Neutrophils >25/ LPF 77- 82% >25/ LPF
SEC <10/LPF <1% <10/ LPF
ICO No data ≥5% No data
Quantitative  culture  threshold 
(cfu / ml )
≥105-106 ≥104 ≥105-106
Antimicrobial susceptibility test:
Antimicrobial  susceptibility  test  of  the  bacterial  isolates  was 
performed  on  Mueller  Hinton  Agar  (Hi-media,  Mumbai)  plates  by  Kirby 
Bauer’s  disc  diffusion  method  and  antibiotic  sensitivity  pattern  studied 
according to Clinical Laboratory Standards Institute (CLSI). 
Gram negative bacilli were tested for the following antimicrobials (Hi-
media, Mumbai): 
Antimicrobial agent Disc content
Gentamicin 10 µg
 Amikacin 30 µg
Amoxycillin/Clavulanic acid 20/10 µg
Cotrimoxazole 25 µg
Cephalexin 30 µg
Cefotaxime 30 µg 
Ceftazidime 30 µg
Ceftriaxone 30 µg 
Cefpodoxime 10 µg
Aztreonam 30 µg  
Cefepime 30 µg 
Ciprofloxacin 5 µg
Ofloxacin 5 µg
Gatifloxacin 5 µg
Imipenem 10 µg 
Gram positive cocci were tested for the following antimicrobials (Hi-
media, Mumbai): 
Antimicrobial agent Disc content
Ampicillin 10 µg
Amoxycillin/Clavulanic acid 20/10 µg 
Oxacillin 1 µg 
Gentamicin 10 µg
Amikacin 30 µg
Cotrimoxazole 25 µg
Cephalexin 30 µg 
Cefuroxime 30 µg
Cefotaxime 30 µg
Ceftazidime 30 µg
Ciprofloxacin 5 µg
Ofloxacin 5 µg
Erythromycin 15 µg 
Vancomycin 30 µg
     Isolates showing inhibition zones ≤22 mm for cetazidime, ≤27 mm for 
cephotaxime, ≤25 mm for ceftriaxone, ≤22mm for Cefpodoxime and ≤27 mm 
for Aztreonam were identified as potential  ESBL producers  70,  73 and they 
were  confirmed  by  Double  disk  potentiation  test  and  Double  disk 
approximation test. 75
Double disk potentiation test: 85
Ceftazidime (30mcg, Himedia, Mumbai) and Ceftazidime -Clavulanic 
acid (30/10mcg, Himedia, Mumbai) discs were placed onto Muellar Hinton 
Agar (MHA) plates inoculated with a suspension (adjusted to 0.5 McFarland 
turbidity  standard)  made  from an  overnight  agar  plate  of  the  test  strain. 
Plates  were  then incubated at  35o C overnight.   Regardless  of  the  zone 
diameter, ≥5 mm increase in a zone diameter for Ceftazidime -Clavulanic 
acid disc than disc with Ceftazidime alone confirmed the presence of ESBL 
producers. 
Double Disk approximation test: 40, 71
A disc of Amoxicillin-Clavulanic acid (20/10mcg, Himedia, Mumbai) 
and  a  disc  of  Ceftazidime (30mcg,  Himedia,  Mumbai)  were  kept  30mm 
apart from center to center on Muellar Hinton Agar (MHA) plates inoculated 
with a suspension (adjusted to 0.5 McFarland turbidity standard) made from 
an overnight agar plate of  the test strain. Plates were then incubated at 35o 
C overnight.  
Enhancement of the zone of inhibition around the Ceftazidime disc 
towards  the  Clavulanic  acid  disc  was  interpreted  as  positive  for  ESBL 
production.
All  cultures of  Klebsiella  pneumoniae were  reconfirmed by colony 
morphology  on  MacConkey  agar,  reaction  in  TSI  agar,  the  absence  of 
motility, absence of Indole production, Negative Methyl Red test, Positive 
Voges-Proskauer  test,  ability  to  grow on Simmon’s  citrate  agar  and the 
decarboxylation of lysine but not ornithine.  Stock cultures of all Klebsiella 
pneumoniae were maintained on NA slants.
KLEBOCIN TYPING:
Media used for klebocin production:
Trypticase Soy Broth (Himedia, Mumbai):
Trypticase peptone 17g
Phytone peptone   3g
NaCl   5g
K2HPO4  2.5g
Glucose 2.5g
Distilled water  1 liter
pH 7.4g
Media used for klebocin typing:
Nutrient agar (Himedia, Mumbai):
Peptone 10g
Meats extract 10g
Sodium chloride 5g
Agar 20g
Water   1 liter
pH  7.4 
Klebsiella stains:
Four Klebocin producer strains, MTCC 109, MTCC 432, MTCC 618 
and MTCC 39 were kindly supplied by Institute of Microbial  Technology,  
Sector  39-A,  Chandigarh  -  160  036,  India  in  the  form  of  freeze  dried 
cultures  in  ampoules.  Two  more  klebocin  producers  (L2  and  L1)  were 
included in the producer strain set. These last two laboratory strains were 
selected for typing set using standard procedures as described by Hall et al, 
59   Bauerfeind et al 62   and Dykes et al. 63   Collectively, the set of producer 
strains used in this study comprised of six klebocin producers as follows: 
MTCC 109 (producer 1), MTCC 432 (producer 2), MTCC 618 (producer 3), 
MTCC 39 (producer 4), L2 (producer 5) and L1 (producer 6).
The indicator  strain  isolated  in  our  laboratory,  sensitive  to  all  six 
klebocins was used as a positive control in klebocin typing. 
Recovery of freeze dried cultures from ampoule:
The  intactness  and  the  identification  label  of  the  ampoule  were 
checked initially. The ampoule was marked with a file transversely over the 
cotton-wool  plug. The tip of  a glass rod was heated red-hot in a Bunsen 
flame and applied firmly to the file mark on the ampoule, which could crack at 
that point. Air was allowed to enter via the plug; then carefully the drawn-out 
end of the ampoule and the plug were put into a container of disinfectant, for  
subsequent autoclaving. With aseptic precautions, a small amount of sterile 
Nutrient  Broth  was  added  to  the  ampoule  with  a  sterile  Pasteur  pipette, 
expressing and taking up the broth several times to bring the contents of the 
ampoule into suspension. The suspended material in the broth was seeded 
into  Trypticase  Soy  Broth  to  ensure  recovery  of  the  organism  after 
appropriate incubation.
Induction of klebocin production: 9
To  each  broth  culture  (about  0.7ml)  of  producer  strains,  3.3  ml 
Trypticase  Soy  Broth  (TSB)  and  1  ml  of  mitomycin  C (0.5mcg/ml)  was 
added and incubated at 37o C for 5 hours with intermittent shaking. 
The  cells  were  killed  by  addition  of  0.25  ml  chloroform.  The 
suspension  was  centrifuged  at  3000  rpm for  10  min  in  cold  centrifuge. 
Supernatant  containing  respective  klebocins  was aliquoted in  screw cap 
vials  and  stored  at  -20o C.  The  purified  preparations  of  klebocins  were 
subjected to  SDS-PAGE which  showed them to  be proteins  having two 
peptides, one of 85kDa and the other of 11kDa.
Klebocin titration: 61
The  klebocins  were  serially  diluted  eightfold  in  Nutrient  Broth, 
ranging from 1:8 to 1:512.  With micropipette 0.025ml of each dilution was 
delivered onto an NA (2% agar) plates (15 by 100 mm) streaked with cotton 
tipped  applicator  that  had  been  moistened  in  a  culture  of  the  Indicator 
strain. This culture was prepared by sub culturing from a work stock culture 
into 2ml of Nutrient Broth and incubating at 37o C for 6 hours. The plates 
were incubated overnight at 37o C.
The highest Dilution of klebocin yielding completely clear inhibition of 
the indicator strain was defined as the Inhibitory Dilution (ID). Control spots 
of chloroform treated TSB containing 1µg of mitomycin C per ml showed no 
inhibition of the indicator strain.
Typing procedure: 9, 61
The test strains were inoculated by a straight needle from NA slants 
into 2 ml of Nutrient broth and incubated at 37o C for six hours. These test 
cultures  were  swabbed  over  a  nutrient  agar  plates  and  12µl  of  each 
klebocin was spot inoculated on marked sectors with a micropipette. The 
plates were incubated overnight at 37o C. 
A  positive  control  plate  swabbed  with  a  six  hours  culture  of  the 
indicator strain was included with every typing.
The readings were  made by grading the  inhibition  seen,  using  a 
scale of no reaction to 4+.
1+ - a partial inhibition with confluent growth.
                                2+    - a partial inhibition showing patches of semi confluent 
growth   or more than 10 colonies.
3+                - a clear zone containing no more than 10 distinct colonies.
4+            - a completely clear zone of inhibition.
All  reactions  that  were  1+  or  greater  were  designated  as  being 
positive, and those that were less than 1+ were designated as negative. 
The negative and positive reactions to six klebocins were recorded, using a 
mnemonics system proposed by Farmer (1976). 
The six klebocins were divided into three pairs. Each combination of 
reactions for a given pair  was assigned a mnemonic notation (Table 3).  
Thus  the  klebocin  type  for  a  given  isolate  is  reported  as  a  mnemonic 
composed of three numbers
Table 3. Mnemonic system for reporting klebocin sensitivity patterns:61
a Inhibition of isolate by both klebocins.
b Inhibition of isolate by first klebocin and no inhibition by second 
klebocin. 
Reproducibility of klebocin typing:   
The reproducibility was determined by using the formula: R = Nr / N, 
where  Nr  is  the  number  of  isolates  assigned  the  same type  on  repeat 
testing and N is the number of isolates tested. 43
Table  4.  Examples  of  klebocin  sensitivity  pattern  using  mnemonic 
system:
Producer 
Strains
Example 1 (Type 211) Example 2 (Type 314)
Reaction Mnemonic 
notation
Reaction Mnemonic 
notation
MTCC 109
MTCC 432
+
−
2
−
+
3
MTCC 618
MTCC 39
+
+
1
+
+
1
L2 
L1
+
+
1
−
−
4
RESULTS
During the one-year study period, among 2658 patients admitted to 
the IMCU, only 2454 cases were followed and included in this study.   The 
remaining 204 cases were excluded. (118 died within 48hrs of admission, 86 
were discharged or went home against advice). 
Among 2454 patients, 64% of patients (n=1570) were males and 36% 
(n=884) were females. The mean age was 59.96 with the range of 15 to 89 yrs 
old. 35% of the patients were more than 60yrs of age. Out of 2454 cases, 
253(10.3%) patients developed HAP. The highest incidence of HAP (55.73%) 
was observed in the age group more than 60 years. (Ref table 5, 6)
The  primary  reason  for  IMCU  admission  was  due  to  neurological 
events (31.1%), cardiac and pulmonary emergencies (26.0%), acute infections 
(12.%5),  poisoning (5.3%),  envenomation  (0.5%),  etc  and the  incidence of 
HAP was greater in patients with  diseases requiring prolonged mechanical 
ventilation and in patients with those diseases that predispose to pulmonary 
infection such as sepsis and prolonged stay in IMCU.
Out  of  1352  patients  on  mechanical  ventilation,  62.0% of  patients 
(n=157) developed HAP and only 38.0% of patients (n=96) developed HAP 
out of 1102 non ventilated patients. (Ref table 7)
Totally 145 sputum samples, 70 BAL and 38 ETA were collected and 
processed. Isolates in pure growth or mixture of two organisms at quantitative 
threshold were considered as significant isolates. All 253 specimens in this 
study showed significant growth of organisms. About  274  organisms  were 
isolated from 253 samples. 
The  commonest  organism  isolated  was  Klebsiella  pneumoniae 
(48.2%)  followed  by  Pseudomonas  aeruginosa  (15.3%),  E.coli  (8.4%), 
Acinetobactor spp (7.7%), Proteus spp (6.9%), MRSA (6.2%), MSSA (5.1%), 
Serratia spp (0.7%), Enterobactor spp (0.7%), Strep.pneumoniae(0.4%) and 
Candida albicans (0.4%). (Ref table 8)
 Twenty  one samples  had showed mixed growth  of  two  organisms 
likewise Klebsiella pneumoniae and Pseudomonas aeruginosa in 15 cultures 
(7 Sputum, 6 BAL & 2 ETA), Klebsiella pneumoniae and E.coli in 3 cultures (2 
Sputum &1 BAL), Klebsiella pneumoniae and MRSA in 2 cultures (1 Sputum & 
1 BAL), Klebsiella pneumoniae and MSSA in 1 sputum culture.
Klebsiella  pneumoniae,  E.coli  and  P.  aeruginosa  had  a  maximum 
sensitivity  pattern  to  Imipenem  followed  by  Cefepime,  Gatifloxacin  and 
Amikacin.  All  Gram  negative  bacterial  isolates  had  100%  sensitivity  to 
Imipenem. Among 132 K.pneumoniae isolates 82% (n=108) were found to be 
ESBL producers. Among 23 E.coli isolates 52% (n=12) were ESBL producers. 
Staphylococcus  aureus  had  a  maximum sensitivity  to  Vancomycin 
followed  by  third  generation  cephalosporins.  No  Vancomycin  resistant 
Staph.aureus was detected. 54.84% (n=17) of Staph.aureus were Methicillin 
Resistant strains. (Ref table 9)
Klebocin  typing  was  performed  on  a  total  of  160  K.pneumoniae 
strains isolated from patients (n=132) and IMCU sites & IMCU staff members 
(n=28).  The overall  typability  of  the strains  was  87.5% and only  12.5% of 
strains  were  untypable.  Nineteen klebocin  types  were  observed.  The most 
common mnemonic type found among patient’s isolates was 211 followed by 
111, 112 and 441. (Ref table 10)  Among the isolates from IMCU sites & staff  
the common mnemonic type was 211. (Ref table 11)  
The Inhibitory Dilution (ID)  for  all  klebocin  preparations was  1:256 
except MTCC 432 klebocin preparations, for which the ID was 1:128.
With  the  exception  of  klebocin  preparations  from  MTCC  432,  the 
reproducibility of klebocin typing was 83% even after four weeks of storage at 
-20oC. 
Klebocin typing and antibiogram of patient’s isolates was compared 
with those from IMCU sites & staff, isolated during the period of infection.  In 
101 (76.51%) cases, the mnemonic types as well as antibiogram of Klebsiella 
pneumoniae isolates from patients matched with those of IMCU sites and staff. 
All  the klebocin type 211 of both patient’s and environmental isolates were 
100% sensitive to Imipenem, 97% sensitive to Cefipime and Fluroquinolones, 
95%  sensitive  to  Amikacin  and  76%  sensitive  to  Gentamicin.  100%  of 
untypable  strains  (444)  (15  patient’s  isolate  and  5  environmental  isolates) 
were sensitive to Imipenem, 93% sensitive to Amikacin, Cefipime, Ofloxacin 
and Gatifloxacin,  80%  to  Ciprofloxacin.  The klebocin type 111 which  was 
isolated from suction tube had similar antibiotic pattern like that of Patient’s 
isolates  (n=9).  All  klebocin  type  111  were  resistant  to  Cotrimoxazole, 
Cephalexin, Cefuroxime, Cefotaxime, Ceftazidime and Ceftriaxone and 100% 
sensitive to Imipenem. This antibiotic sensitivity pattern was similar to that of 
klebocin type 112 (1 from throat of the IMCU staff and 7 from HAP patients). 
(Ref table 12)  
  
 
  
 Table 5. Age -wise distribution of patients.
Age (yrs) Total patients Patients with HAP (n) (%)
0-15 10 0(0)
16-30 349 7(2.77)
31-40 414 13(5.14)
41-60 882 92(36.36)
>60 859 141(55.73)
Total 2454 253
Table 6. Age and sex- wise distribution of patients.
Age(yrs)
Male Female
Total With HAP Total With HAP
<15 6 - 4 -
16-30 223 5 126 2
31-40 288 9 126 4
41-60 551 59 271 33
>60 502 102 357 39
Total 1570 175 884 78
Table 7. Influence of mechanical ventilation on HAP.
Ventilator Total Patients with HAP (%)
Yes 1352 157(62.0)
No 1102 96(38.0)
Total 2454 253
Table 8. Pathogens isolated from HAP patients.
Pathogens isolated No of isolates (n=274) (%)
K.pneumoniae 132 (48.2)
P.aeruginosa 42 (15.2)
E.coli 23 (8.4)
Proteus spp 19 (6.9)
Acinetobactor spp. 21 (7.7)
Serratia 2 (0.7)
Enterobactor spp. 2 (0.7)
MSSA 14 (5.1)
MRSA 17 (6.2)
Strep. pneumoniae 1 (0.4)
Candida albicans 1 (0.4)
Table 9. Antimicrobial susceptibility pattern of Bacterial isolates.
ANTIMICROBIAL
AGENT
Disc content(µg)
K.
pn
eu
m
on
ia
e 
(1
32
)
P.
ae
ro
gi
no
sa
 (4
2)
E.
co
li 
(2
3)
Ac
in
et
ob
ac
to
r(2
1)
Pr
ot
eu
s 
sp
 (1
9)
Se
rra
tia
 (2
)
En
te
ro
ba
ct
or
 s
p 
(2
)
St
ap
h.
au
re
us
 (3
1)
St
r. 
Pn
eu
m
on
ia
e 
(1
)
Gentamicin (10) 75 21 13 13 15 2 1 14 1
Amikacin  (30) 121 27 22 17 19 2 2 19 1
Ampicillin (10) - - - - - - - 16 1
Oxacillin  (1) - - - - - - - 14 1
AmoxyClav(20/10) 29 0 7 - - - - 24 1
Cotrimoxazole(25) 44 4 11 4 11 1 2 7 0
Cephalexin(30) 8 16 8 12 10 1 0 26 1
Cefuroxime(30) 8 16 8 12 10 2 1 26 1
Cefotaxime(30) 21 39 13 21 18 2 2 29 1
Ceftazidime(30) 21 39 14 21 19 2 2 27 1
Cefepime(30) 127 42 23 21 19 2 2 - -
Ciprofloxacin(5) 102 30 12 12 17 2 1 23 1
Ofloxacin(5) 123 31 12 17 17 2 2 25 1
Gatifloxacin(5) 127 40 20 18 19 2 2 -     -
Imipenem(10) 132 42 23 21 19 2 2 - -
Erythromycin(15) - - - - - - - 26 1
Vancomycin(30) - - - - - - - 31 1
Table 10. Mnemonic types of Klebsiella pneumoniae isolates.
Mnemonic types Patient’s strains IMCU 
sites
IMCU 
Staff
Total no. of strains
(%)
211 70 12 9 91(56.8%)
444 15 2 3 20(12.5%)
111 9 1 − 10(6.2%)
112 7 − 1 8(5.0%)
441 6 − − 6(3.7%)
311 4 − − 4(2.5%)
241 3 − − 3(1.8%)
314 3 − − 3(1.8%)
414 2 − − 2(1.2%)
341 2 − − 2(1.2%)
243 2 − − 2(1.2%)
312 2 − − 2(1.2%)
221 1 − − 1(0.6%)
231 1 − − 1(0.6%)
141 1 − − 1(0.6%)
332 1 − − 1(0.6%)
411 1 − − 1(0.6%)
412 1 − − 1(0.6%)
244 1 − − 1(0.6%)
Total no. of strains 132 15 13 160
Typability 88.64% 86.66% 76.92% 87.5%
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  Table 11.  Source and mnemonic types of Klebsiella pneumoniae.
Mnemonic 
type
IMCU staff IMCU sites
Throat Hand Nose Suction 
tube
Trolley Wall Curtains
211 5 3 1 8 3 - 1
444 2 1 - - 1 1 -
111 - - - 1 - - -
112 1 - - - - - -
Total 8 4 1 9 4 1 1
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        Table 12. Antimicrobial sensitivity pattern and klebocin type of 
Klebsiella pneumoniae isolates from HAP Patients and IMCU sites 
& staff.
ANTIMICROBIAL 
AGENT
Disc content(µg)
Klebocin Type
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Gentamicin (10)
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1
6 8 3 7 1 4 1
Amikacin  (30)
6
7
2
0
1
4 4 8 1 5 1
AmoxyClav(20/10)
1
6 5 8 3 4 1 3 1
Cotrimoxazole(25)
4
0
1
2 6 2 0 0 0 0
Cephalexin(30) 3 1 2 1 0 0 0 0
Cefuroxime(30) 3 1 2 1 0 0 0 0
Cefotaxime(30) 7 2 8 3 0 0 0 0
Ceftazidime(30) 7 2 8 3 0 0 0 0
Cefepime(30)
6
8
2
0
1
4 4 7 1 7 1
Ciprofloxacin(5)
6
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1
2 4 6 1 6 1
Ofloxacin(5)
6
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1
4 4 6 1 6 1
Gatifloxacin(5)
6
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1
4 4 8 1 7 1
Imipenem(10)
7
0
2
1
1
5 5 9 1 7 1
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DISCUSSION
. The present study showed that the incidence of HAP was 10.3% 
(n=253) out of 2454 cases admitted in IMCU, Coimbatore Medical College 
Hospital over a period of one year. 
This incidence was lower than the study by Mukhopadhyay et al  
from Lucknow (53.9%), 18 Rakshit et al from Mumbai (47%), 13  Vincent et al 
from Europe (46.9%),  25  Dey et al from Manipal (45.4%),  15   Sopena et al 
from  Spain  (36.4%),  30    Berba  et  al  from Philadelphia  (28.2%)  33  and 
Merchant et al from Mumbai (16.7%). 19  This was higher than the incidence 
reported  by  Chevret  et  al  from  France  (8.9%),  29   Alp  et  al  from 
Netherlands(6.8%),  32  Trivedi et al from Mumbai (9.38%)16  and Pawar et al 
from New Delhi (2.6%). 14
It is possible that our incidence rate may be an over estimate of the 
HAP  in  the  hospital  because  of  the  nature  of  the  clinical  criteria  used. 
Studies based solely on clinical criteria alone are criticized because of the 
non-specificity of parameters like fever, leukocytosis and infiltrates on the 
chest  radiographs.  However,  the  stringent  steps  followed  to  make  a 
diagnosis of HAP in this study and the close monitoring before and after the 
diagnosis of HAP occurred should make our estimate very close to the true 
HAP incidence. It is unlikely that a true HAP case would have been missed 
because we  did  quantitative  culture  of  all  specimens (BAL,  Sputum and 
ETA) to discriminate between the true pathogen and the contaminant using 
the diagnostic threshold for each specimen.
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High occurrence (55.73%) of HAP among the age group more than 
60 years was observed in the present study. This could be due to the bulk of 
the study population in this study was more 60 years of age group. This was  
in accordance with an earlier study by Berba et al.  33   Age more than 60 
years is one of the known risk factor for the development of HAP as reported 
in previous studies. 1, 27   But Muhammad et al reported that highest incidence 
was among 41 to 60 years of age group. 22    
The  present  study  showed  that  the  incidence  of  HAP  was  high 
among male patients than females.  This finding was similar to the study by 
Mukhopadhyay et al from Lucknow. 18 But Berba et al showed that the male 
sex had a protective effect against the development of HAP.  33   Dey et al 
reported that gender had no significant role in the development of HAP. 15    
In the present study the incidence of HAP was greater in patients 
with diseases requiring prolonged mechanical ventilation like OP poisoning 
(15.0%) and considerably low in patients with diseases which presumably, 
had unaffected lungs before admission to IMCU like snake bite (0.4%). These 
findings were similar to the previous studies. 13, 15   
HAP developed in 157 out of  the 1352 patients (62.0%) receiving 
mechanical ventilation but in only 96 out of 1102 patients (38.0%) with no 
mechanical ventilation. This incidence of VAP (62.0%) was higher than the 
study by Muhammad et al (30.7%)  22  and lower than the study by Alp et al 
who showed that 75.5% of all patients with HAP were VAP. 32   
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Mechanical ventilation is a definitive risk factor for developing HAP 
that has been shown previously by many studies  15,  18 and this study also 
shows the significance of that risk factor causing HAP.
Klebsiella  pneumoniae  (48.2%)  was  the  commonest  organism 
isolated in this study.  Most of the previous studies reported Pseudomonas 
aeruginosa as the commonest isolate from HAP patients in IMCU.  35, 14, 13, 18 
But  Pseudomonas  aeruginosa  was  the  second  common  organism  in  the 
present study.  Acinetobacter spp (7.7%) was the fourth common isolate in 
this  study.  Dey  et  al,  Rajasekhar  et  al  and  Alp  et  al  reported  that 
Acinetobacter spp as the commonest organism in their study. 15, 23, 32   E. coli 
was the commonest  organism in  the study by Tullu  et  al.  17  It  was  third 
commonest organism in the present study. These findings indicate that the 
causative  pathogens  always  vary  in  different  setups.  The  present  study 
suggests that the colonization rate for Klebsiella pneumoniae may be higher 
in IMCU.
The rate of polymicrobial infection was found to be only 8.3% in this 
study which was lower than the study by Mukhopadhyay et al (16.3%) 18   and 
Singhal et al (12.3%). 83   The lower rate of colonization of  IMCU environment 
by  more  than  one  type  of  organisms  may  be  the  reason  for  the  lower 
incidence of polymicrobial infection.  
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Antimicrobial  resistance among Gram negative bacilli  is  increasing 
worldwide and is of particular concern in the Intensive Care Unit setting. A 
direct  correlation  has  been  shown  between  resistance  of  Gram  negative 
bacilli  and patient  mortality,  cost  of  patient  care and length of  stay in  the 
hospital. 76   In a study by Kaul et al about the Gram- negative bacterial 
antibiotic susceptibility patterns in IMCU, Christian Medical College, Vellore 
showed that Klebsiella resistance to cefotaxime and ceftazidime ranged from 
25-50% and 14-91%, while E.coli resistance to these antibiotics ranged from 
50-70% and 50-80% respectively.  81    In this study Klebsiella resistance to 
cefotaxime  and  ceftazidime  was  84%  and  E.coli  resistance  to  these 
antibiotics were 43% and 39% respectively.  The resistance of K.pneumoniae 
and E.coli to third generation cephalosporins was higher in this study. 
All  isolates  of  Acinetobacter,  Serratia  and  Enterobactor  were 
sensitive  to  third  generation  cephalosporins.  92%  of  Pseudomonas 
aeruginosa and 94% of Proteus were sensitive to cefotaxime and ceftazidime. 
These findings were similar to the study by Kaul et al from Christian Medical 
College,  Vellore,  who  reported  that  in  Pseudomonas  aeruginosa  and  the 
other  non-fermenting  gram-negative  bacteria  (NFGNB)  Ceftazidime 
resistance  decreased.  Among  Aminoglycosides,  most  of  the  GNB  were 
sensitive  to  Amikacin  than  Gentamicin.  Highest  sensitivity  rates  were 
detected for Gatifloxacin than Ciprofloxacin and Ofloxacin among Quinolones. 
These findings were similar to previous studies on antimicrobial  resistance 
among gram-negative bacteria by many authors. 21, 22, 23, 39, 64 
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All  Gram  negative  bacilli  isolated  in  this  study  had  a  maximum 
sensitivity pattern to Imipenem and Cefepime. This was similar to the study by 
Lockhart  et  al  about  antimicrobial  resistance among Gram-Negative Bacilli 
causing  infections  in  Intensive  Care  Unit  patients  in  the  United  States 
between 1993 and 2004 76  and Rakshit et al from Mumbai. 13
   Gram-negative bacilli producing ESBL appear to be on the rise in 
Asian countries and pose a serious problem in pulmonary infections. 80   In the 
present study the occurrence of ESBL production among K.pneumoniae and 
E.coli were 82% and 52% respectively. For Klebsiella pneumoniae this finding 
was  higher  than  the  study by  Feizabadi  et  al  (72.8%),  74   Gonlugur  et  al 
(12.2%),  39   Hosoglu et al (68.3%),  72    Asian HAP Working group (0.9% to 
40%) 80   and lower than the study by Verhamme et al (100%), 79 Vitkauskiene 
et al (88.9%), 84  Dey et al (100%).  15     For  E.coli  this  finding  was  higher 
than the study by Gonlugur et al (20.8%), 39  Asian HAP Working group (2.3% 
to 40%) 80   and lower than the study by Hosoglu et al (74.6%), 72   Dey et al 
(100%).  15    
 In  this  study  ESBLs  were  predominantly  present  among  K. 
pneumoniae compared to E. coli. Our findings are similar to that of most of 
the studies in Europe and USA 38  and the Indian studies by Jain et al  64 and 
Shanmuganathan et al. 65     But studies by Gonlugur et al, 39   Hosoglu et al 72 
and Kumar et al  82    showed higher incidence of ESBLs among E.coli than 
K.pneumoniae. The indiscriminate use of third-generation cephalosporins has 
been proposed as a reason for the rise of ESBL producing strains in India. 80
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Among  the  Staphylococcus  aureus  isolates  in  this  study,  the 
occurrence  of  Methicillin  resistance  was  observed  in  54.84%.  This  was 
higher than the study by Leroy et al (33%)  35 and lower than the study by 
Mukhopadhyay et al (59.45%) 18 and Rakshit et al (100%). 13 No Vancomycin 
resistant Staphylococcus aureus was detected in the present study.  
Epidemiological  investigation  of  nosocomial  infections  is  greatly 
facilitated by the use of a precise typing system for the organism involved. 
Our study about the hospital acquired pneumonia in IMCU suggests a high 
prevalence of Klebsiella pneumoniae accounting for 48.2% of total cases. In 
the present study, we have used Klebocin typing and antibiotic sensitivity 
profiles  as  the  typing  methods  for  the  detection  of  source  of  Klebsiella 
infections in our IMCU. Although not comparable to molecular methods in 
discriminatory  power,  antibiogram  and  klebocin  typing  are  simpler  and 
relatively economical method of bacteriological typing. 
In  the  present  study  all  Klebsiella  pneumoniae  isolates  were 
subjected to klebocin typing by spot inoculation method as described by Pal 
et al who done the klebocin typing in their study by spot inoculation method 
which was described by Chugh et al with some modifications. Using the spot 
inoculation method, we observed 87.5% typability, whereas   Buffenmyer et 
al, 61    Chibber et al, 60 Malik et al, 43 Aggarwal et al 44   and Pal et al 9    reported 
67%, 72.8%, 83.3%, 73.5% and 71.62% typability respectively. Bauernfeind 
et al ,62   Hall, 59   Israil 46    and  Podschun et al 58  have reported 96.3%, 77%, 
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85%  and  96%  typability  respectively  using  streak  and  point  method  for 
klebocin typing. 
Despite the relatively higher typability observed in streak and point 
method,  we  followed  the  spot  inoculation  method.  In  view  of  the  high 
induction of klebocins by mitomycin C, storage stability at -20oC and simplicity 
of the technique, spot inoculation method is more appropriate typing method.9
Nineteen klebocin types were observed in the present study using six 
klebocin producer strains. Pal et al reported that twenty eight klebocin types 
had  been  observed  in  their  study  using  six  klebocin  producer  strains  9 
whereas Malik et al observed four patterns of klebocin types in their study 
with six klebocin producer strains. 43  
 We observed  the  klebocin  types  211  (56.8%),  111  (6.2%),  112 
(5.0%) and 441 (3.7%) were the most common types in our study. According 
to Buffenmyer et al and other previous studies type 444 was considered as 
untypable and these strains accounted for 12.5% of the total strains studied. 
Pal  et  al  reported  types  111  (50%),  211  (5.59%),  312  (3.08%)  and  112 
(2.31%) as the commonest klebocin types in their study and 28.37% strains 
could not be typed. 9   
Malik et al found type 312 (43.4%) as the commonest followed by 
type 334 (23.4%), type 112 (16.6%) while remaining 16.6% strains could not 
be typed. 
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Chibber  et  al  reported  the  predominant  klebocin  types  as  244 
(14.3%),  313  (13.7%)  and  113  (7.6%).  60    Aggarwal  et  al  observed  the 
commonest klebocin types as 111, 313 and 113. Probably there is variation in  
the prevalence of various klebocin types in different topographical areas and 
institutions. Moreover the set of producer strains used in the present study 
was different from other studies in which they had used a set of producer 
strains standardized by them in their own setups. It  is therefore difficult  to 
compare our typing patterns with other studies.
In the present study, we found that by combination of klebocin types 
and antibiogram of K.pneumoniae isolates, the source of infection could be 
traced in 76.51% cases. In a study on klebocin typing by Chibber et al 60 no 
significant correlation was observed between the source of isolation and the 
klebocin type whereas Pal et al  9    observed when the klebocin typing was 
used in association with antibiogram, in 86.84% cases probable source of 
infection could be detected.
Despite the importance of the findings presented in this study, there 
are some limitations that should be taken into consideration when assessing 
our conclusions. First, although for the diagnosis of HAP we did quantitative 
culture of Sputum, BAL and ETA, yet the results from this study need to be 
validated by comparison to gold standards such as histology of lung tissue.
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Last, in the present study the reproducibility of the klebocin typing 
was 83%. This was higher than the previous study by Malik et al who showed 
in their study that the reproducibility of the klebocin typing was 73.3%. 43   This 
is  of  major  concern because a useful  and effective  epidemiological  typing 
system should have high reproducibility. In our study the reproducibility may 
be a major problem with  the klebocin typing procedure. This difficulty was 
primarily due to the sensitivity of the test strains to MTCC 432 klebocin and 
was presumably associated with their low titers. This problem was a serious 
shortcoming since, as shown in Table 10 the commonest type in our study 
was 211. This pattern of typing was due to lack of sensitivity of the clinical 
isolates to MTCC 432 klebocin (producer 2). Replacing the producer strain of 
this klebocin with  the strain that yields high-titer  preparations may help in 
achieving  acceptable  reproducibility.  Such  strains  may  be  obtained  by 
screening  Klebsiella  pneumoniae  isolates  for  klebocin  activity  or  testing 
producer strains of other investigators.
In spite of these problems, this study proposed the klebocin typing in 
association with antibiogram as a tool for epidemiological typing of Klebsiella 
pneumoniae  isolates  in  the  laboratories  where  the  facilities  to  perform 
genomic  based  molecular  typing  are  not  available.  The  advantages  of 
klebocin typing include (i) the ready availability of required materials in most 
bacteriological  laboratories,  (ii)  the  ability  to  perform the  typing  procedure 
within the usual work day, and (iii) the ability to store the klebocins for future  
use. 
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SUMMARY
• 2454 cases admitted in IMCU, Coimbatore Medical College Hospital, 
Coimbatore were studied over a period of one year from May 1, 2007 
to April 30, 2008.
• 1570 males and 884 females were in the study.
• The overall incidence of HAP was 10.3%. 
• The incidence of VAP was 62.0%.
• The incidence of HAP was higher (55.73%) in the age group more than 
60 years.
• The  274  organisms  were  isolated  from  253  lower  respiratory  tract 
samples.
• The incidence of polymicrobial infection was 8.3%.
• Klebsiella pneumoniae (48.2%) was the commonest organism isolated. 
This was followed by Pseudomonas aeruginosa (15.3%), E.coli (8.4%), 
Acinetobactor  spp  (7.7%),  Proteus  spp  (6.9%),  MRSA  (6.2%),  and 
MSSA (5.1%).
• All Gram-negative bacilli were 100% sensitive to Imipenem.
• All  Gram-negative  bacilli  were  100%  sensitive  to  Cefepime  and 
Gatifloxacin except Klebsiella pneumoniae which was 96% sensitive to 
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Cefepime and Gatifloxacin, Pseudomonas aeruginosa which was 95% 
sensitive  to  Gatifloxacin  and  E.coli  which  was  87%  sensitive  to 
Gatifloxacin.
• 92% of Pseudomonas aeruginosa and 94% of Proteus were sensitive 
to third generation cephalosporins.
• The  screening  for  the  ESBL  producing  GNB  was  done  with 
Cetazidime, Cephotaxime, Ceftriaxone, Cefpodoxime and Aztreonam 
by Kirby Bauer’s disc diffusion method.
• The  confirmation  of  ESBL  production  was  done  by  Double  disk 
potentiation test and Double disk approximation test.
• 82% of  K.pneumoniae  and  52% of  E.coli  were  extended  spectrum 
beta-lactamase producing strains.
• Staphylococcus aureus was 100% sensitive to Vancomycin.
• 54.84% of Staphylococcus aureus were Methicillin Resistant strains.
• Number of Klebsiella pneumoniae isolated from IMCU sites and Staff 
was 28.
• Induction of klebocin production from six producer strains was done 
with mitomycin C.
• Presence of klebocins was confirmed by SDS-PAGE.
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• Klebocin typing  was done for  a total  of  160 K.pneumoniae isolated 
from HAP patients and IMCU sites & staff.
• Nineteen klebocin types were  observed using six klebocin producer 
strains.
• The typability  of  klebocin typing  was  87.5% by the spot  inoculation 
method.
• 211 (56.8%) was the commonest klebocin type followed by 111 (6.2%), 
112 (5.0%) and 441 (3.7%).
• The untypable strain (444) accounted for 12.5%.
• The reproducibility of the klebocin typing was 83%.
• The source of Klebsiella infection was detected in 86.84% of cases 
using klebocin typing and antibiogram.
• The  commonest  source  of  Klebsiella  infection  in  our  IMCU  were 
suction tube (32%), throat of the IMCU staff (29 %), hands of the IMCU 
staff (14%) and trolley (14%).
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CONCLUSION
  This one year prospective study on 2454 cases admitted in IMCU, 
Coimbatore Medical College Hospital was conducted in order to study the 
incidence,  the  Clinical  and  Bacteriological  profile  of  HAP,  the  antibiotic 
susceptibility pattern of the bacterial isolates, the role of Klebocin typing in 
epidemiological typing of K.pneumoniae strains and the source of infection 
in IMCU using antibiogram and klebocin typing.
The incidence of HAP was 10.3% with the occurrence being most in 
the age group more than 60 years. Mechanical ventilation was a important 
risk factor for the development of HAP. Klebsiella pneumoniae, Pseudomonas 
aeruginosa,  E.coli,  Acinetobacter,  Proteus spp,  and MRSA were  the most 
common bacterial isolates. 
The most  effective  antibiotics against  the GNB isolated from HAP 
patients were Imipenem followed by Cefepime and Gatifloxacin. The antibiotic 
susceptibility  pattern  of  the  isolates  will  help  the  clinicians  to  choose  the 
appropriate  antimicrobial  agents  for  prophylactic  as  well  as  treatment 
purposes.
When klebocin typing was used in association with antibiogram, in 
86.84% cases of nosocomial Klebsiella infection probable source of infection 
could be detected. Thus a combination of these two typing methods poses a 
contribution in epidemiological studies.
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RESULTS
During the one-year study period, among 2658 patients admitted to 
the IMCU, only 2454 cases were followed and included in this study.  The 
remaining 204 cases were excluded. (118 died within 48hrs of admission, 86 
were discharged or went home against advice). 
Among 2454  patients,  64% of  patients  (n=1570)  were  males  and 
36% (n=884) were females. The mean age was 59.96 with the range of 15 to 
89 yrs old. 35% of the patients were more than 60yrs of age. Out of 2454 
cases, 253(10.3%) patients developed HAP. The highest incidence of HAP 
(55.73%) was observed in the age group more than 60 years. (Ref table 5, 6)
The primary  reason  for  IMCU admission  was  due  to  neurological 
events  (31.1%),  cardiac  and  pulmonary  emergencies  (26.0%),  acute 
infections  (12.%5),  poisoning  (5.3%),  envenomation  (0.5%),  etc  and  the 
incidence of HAP was greater in patients with diseases requiring prolonged 
mechanical ventilation and in patients with those diseases that predispose to 
pulmonary infection such as sepsis and prolonged stay in IMCU.
Out of  1352 patients  on mechanical  ventilation,  62.0% of  patients 
(n=157) developed HAP and only 38.0% of patients (n=96) developed HAP 
out of 1102 non ventilated patients. (Ref table 7)
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Totally 145 sputum samples, 70 BAL and 38 ETA were collected and 
processed. Isolates in pure growth or mixture of two organisms at quantitative 
threshold were considered as significant isolates. All 253 specimens in this 
study showed significant growth of organisms. About  274  organisms  were 
isolated from 253 samples. 
The  commonest  organism  isolated  was  Klebsiella  pneumoniae 
(48.2%)  followed  by  Pseudomonas  aeruginosa  (15.3%),  E.coli  (8.4%), 
Acinetobactor spp (7.7%), Proteus spp (6.9%), MRSA (6.2%), MSSA (5.1%), 
Serratia spp (0.7%), Enterobactor spp (0.7%), Strep.pneumoniae(0.4%) and 
Candida albicans (0.4%). (Ref table 8)
 Twenty one samples had showed mixed growth of two organisms 
likewise Klebsiella pneumoniae and Pseudomonas aeruginosa in 15 cultures 
(7 Sputum, 6 BAL & 2 ETA), Klebsiella pneumoniae and E.coli in 3 cultures (2 
Sputum &1 BAL), Klebsiella pneumoniae and MRSA in 2 cultures (1 Sputum 
& 1 BAL), Klebsiella pneumoniae and MSSA in 1 sputum culture.
Klebsiella  pneumoniae,  E.coli  and P.  aeruginosa had a  maximum 
sensitivity  pattern  to  Imipenem  followed  by  Cefepime,  Gatifloxacin  and 
Amikacin.  All  Gram  negative  bacterial  isolates  had  100%  sensitivity  to 
Imipenem. Among 132 K.pneumoniae isolates 82% (n=108) were found to be 
ESBL  producers.  Among  23  E.coli  isolates  52%  (n=12)  were  ESBL 
producers. 
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Staphylococcus aureus had a maximum sensitivity  to  Vancomycin 
followed  by  third  generation  cephalosporins.  No  Vancomycin  resistant 
Staph.aureus was detected. 54.84% (n=17) of Staph.aureus were Methicillin 
Resistant strains. (Ref table 9)
Klebocin  typing  was  performed  on  a  total  of  160  K.pneumoniae 
strains isolated from patients (n=132) and IMCU sites & IMCU staff members 
(n=28).  The overall  typability of  the strains was 87.5% and only 12.5% of 
strains were untypable. Nineteen klebocin types were observed. The most 
common mnemonic type found among patient’s isolates was 211 followed by 
111, 112 and 441. (Ref table 10)  Among the isolates from IMCU sites & staff  
the common mnemonic type was 211. (Ref table 11)  
The Inhibitory Dilution (ID) for all  klebocin preparations was 1:256 
except MTCC 432 klebocin preparations, for which the ID was 1:128.
With  the  exception  of  klebocin  preparations  from MTCC 432,  the 
reproducibility of klebocin typing was 83% even after four weeks of storage at 
-20oC. 
Klebocin typing and antibiogram of patient’s isolates was compared 
with those from IMCU sites & staff, isolated during the period of infection.  In 
101 (76.51%) cases, the mnemonic types as well as antibiogram of Klebsiella 
pneumoniae isolates from patients matched with  those of  IMCU sites and 
staff.  All the klebocin type 211 of both patient’s and environmental isolates 
were  100%  sensitive  to  Imipenem,  97%  sensitive  to  Cefipime  and 
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Fluroquinolones, 95% sensitive to Amikacin and 76% sensitive to Gentamicin. 
100% of untypable strains (444)  (15 patient’s isolate and 5 environmental 
isolates) were sensitive to Imipenem, 93% sensitive to Amikacin, Cefipime, 
Ofloxacin  and  Gatifloxacin,  80%  to  Ciprofloxacin.  The  klebocin  type  111 
which was isolated from suction tube had similar antibiotic pattern like that of 
Patient’s isolates (n=9). All klebocin type 111 were resistant to Cotrimoxazole, 
Cephalexin, Cefuroxime, Cefotaxime, Ceftazidime and Ceftriaxone and 100% 
sensitive to Imipenem. This antibiotic sensitivity pattern was similar to that of 
klebocin type 112 (1 from throat of the IMCU staff and 7 from HAP patients). 
(Ref table 12)  
   Table 5. Age -wise distribution of patients.
Age (yrs) Total patients Patients with HAP (n) (%)
0-15 10 0(0)
16-30 349 7(2.77)
31-40 414 13(5.14)
41-60 882 92(36.36)
>60 859 141(55.73)
Total 2454 253
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Table 6. Age and sex- wise distribution of patients.
Age(yrs)
Male Female
Total With HAP Total With HAP
<15 6 - 4 -
16-30 223 5 126 2
31-40 288 9 126 4
41-60 551 59 271 33
>60 502 102 357 39
Total 1570 175 884 78
Table 7. Influence of mechanical ventilation on HAP.
Ventilator Total Patients with HAP (%)
Yes 1352 157(62.0)
No 1102 96(38.0)
Total 2454 253
Table 8. Pathogens isolated from HAP patients.
Pathogens isolated No of isolates (n=274) (%)
K.pneumoniae 132 (48.2)
P.aeruginosa 42 (15.2)
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E.coli 23 (8.4)
Proteus spp 19 (6.9)
Acinetobactor spp. 21 (7.7)
Serratia 2 (0.7)
Enterobactor spp. 2 (0.7)
MSSA 14 (5.1)
MRSA 17 (6.2)
Strep. pneumoniae 1 (0.4)
Candida albicans 1 (0.4)
Table 9. Antimicrobial susceptibility pattern of Bacterial isolates.
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Gentamicin (10) 75 21 13 13 15 2 1 14 1
Amikacin  (30) 121 27 22 17 19 2 2 19 1
Ampicillin (10) - - - - - - - 16 1
Oxacillin  (1) - - - - - - - 14 1
AmoxyClav(20/10) 29 0 7 - - - - 24 1
Cotrimoxazole(25) 44 4 11 4 11 1 2 7 0
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Cephalexin(30) 8 16 8 12 10 1 0 26 1
Cefuroxime(30) 8 16 8 12 10 2 1 26 1
Cefotaxime(30) 21 39 13 21 18 2 2 29 1
Ceftazidime(30) 21 39 14 21 19 2 2 27 1
Cefepime(30) 127 42 23 21 19 2 2 - -
Ciprofloxacin(5) 102 30 12 12 17 2 1 23 1
Ofloxacin(5) 123 31 12 17 17 2 2 25 1
Gatifloxacin(5) 127 40 20 18 19 2 2 -     -
Imipenem(10) 132 42 23 21 19 2 2 - -
Erythromycin(15) - - - - - - - 26 1
Vancomycin(30) - - - - - - - 31 1
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Table 10. Mnemonic types of Klebsiella pneumoniae isolates.
Mnemonic types Patient’s strains IMCU 
sites
IMCU 
Staff
Total no. of strains
(%)
211 70 12 9 91(56.8%)
444 15 2 3 20(12.5%)
111 9 1 − 10(6.2%)
112 7 − 1 8(5.0%)
441 6 − − 6(3.7%)
311 4 − − 4(2.5%)
241 3 − − 3(1.8%)
314 3 − − 3(1.8%)
414 2 − − 2(1.2%)
341 2 − − 2(1.2%)
243 2 − − 2(1.2%)
312 2 − − 2(1.2%)
221 1 − − 1(0.6%)
231 1 − − 1(0.6%)
141 1 − − 1(0.6%)
332 1 − − 1(0.6%)
411 1 − − 1(0.6%)
412 1 − − 1(0.6%)
244 1 − − 1(0.6%)
Total no. of strains 132 15 13 160
Typability 88.64% 86.66% 76.92% 87.5%
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  Table 11.  Source and mnemonic types of Klebsiella pneumoniae.
Mnemonic 
type
IMCU staff IMCU sites
Throat Hand Nose Suction 
tube
Trolley Wall Curtains
211 5 3 1 8 3 - 1
444 2 1 - - 1 1 -
111 - - - 1 - - -
112 1 - - - - - -
Total 8 4 1 9 4 1 1
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        Table 12. Antimicrobial sensitivity pattern and klebocin type of 
Klebsiella pneumoniae isolates from HAP Patients and IMCU sites 
& staff.
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DISCUSSION
. The present study showed that the incidence of HAP was 10.3% 
(n=253) out of 2454 cases admitted in IMCU, Coimbatore Medical College 
Hospital over a period of one year. 
This incidence was lower than the study by Mukhopadhyay et al  
from Lucknow (53.9%), 18 Rakshit et al from Mumbai (47%), 13  Vincent et al 
from Europe (46.9%),  25  Dey et al from Manipal (45.4%),  15   Sopena et al 
from  Spain  (36.4%),  30    Berba  et  al  from Philadelphia  (28.2%)  33  and 
Merchant et al from Mumbai (16.7%). 19  This was higher than the incidence 
reported  by  Chevret  et  al  from  France  (8.9%),  29   Alp  et  al  from 
Netherlands(6.8%),  32  Trivedi et al from Mumbai (9.38%)16  and Pawar et al 
from New Delhi (2.6%). 14
It is possible that our incidence rate may be an over estimate of the 
HAP  in  the  hospital  because  of  the  nature  of  the  clinical  criteria  used. 
Studies based solely on clinical criteria alone are criticized because of the 
non-specificity of parameters like fever, leukocytosis and infiltrates on the 
chest  radiographs.  However,  the  stringent  steps  followed  to  make  a 
diagnosis of HAP in this study and the close monitoring before and after the 
diagnosis of HAP occurred should make our estimate very close to the true 
HAP incidence. It is unlikely that a true HAP case would have been missed 
because we  did  quantitative  culture  of  all  specimens (BAL,  Sputum and 
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ETA) to discriminate between the true pathogen and the contaminant using 
the diagnostic threshold for each specimen.
High occurrence (55.73%) of HAP among the age group more than 
60 years was observed in the present study. This could be due to the bulk of 
the study population in this study was more 60 years of age group. This was  
in accordance with an earlier study by Berba et al.  33   Age more than 60 
years is one of the known risk factor for the development of HAP as reported 
in previous studies. 1, 27   But Muhammad et al reported that highest incidence 
was among 41 to 60 years of age group. 22    
The  present  study  showed  that  the  incidence  of  HAP  was  high 
among male patients than females.  This finding was similar to the study by 
Mukhopadhyay et al from Lucknow. 18 But Berba et al showed that the male 
sex had a protective effect against the development of HAP.  33   Dey et al 
reported that gender had no significant role in the development of HAP. 15    
In the present study the incidence of HAP was greater in patients 
with diseases requiring prolonged mechanical ventilation like OP poisoning 
(15.0%) and considerably low in patients with diseases which presumably, 
had unaffected lungs before admission to IMCU like snake bite (0.4%). These 
findings were similar to the previous studies. 13, 15   
HAP developed in 157 out of  the 1352 patients (62.0%) receiving 
mechanical ventilation but in only 96 out of 1102 patients (38.0%) with no 
mechanical ventilation. This incidence of VAP (62.0%) was higher than the 
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study by Muhammad et al (30.7%)  22  and lower than the study by Alp et al 
who showed that 75.5% of all patients with HAP were VAP. 32   
Mechanical ventilation is a definitive risk factor for developing HAP 
that has been shown previously by many studies  15,  18 and this study also 
shows the significance of that risk factor causing HAP.
Klebsiella  pneumoniae  (48.2%)  was  the  commonest  organism 
isolated in this study.  Most of the previous studies reported Pseudomonas 
aeruginosa as the commonest isolate from HAP patients in IMCU.  35, 14, 13, 18 
But  Pseudomonas  aeruginosa  was  the  second  common  organism  in  the 
present study.  Acinetobacter spp (7.7%) was the fourth common isolate in 
this  study.  Dey  et  al,  Rajasekhar  et  al  and  Alp  et  al  reported  that 
Acinetobacter spp as the commonest organism in their study. 15, 23, 32   E. coli 
was the commonest  organism in  the study by Tullu  et  al.  17  It  was  third 
commonest organism in the present study. These findings indicate that the 
causative  pathogens  always  vary  in  different  setups.  The  present  study 
suggests that the colonization rate for Klebsiella pneumoniae may be higher 
in IMCU.
The rate of polymicrobial infection was found to be only 8.3% in this 
study which was lower than the study by Mukhopadhyay et al (16.3%) 18   and 
Singhal et al (12.3%). 83   The lower rate of colonization of  IMCU environment 
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by  more  than  one  type  of  organisms  may  be  the  reason  for  the  lower 
incidence of polymicrobial infection.  
Antimicrobial  resistance among Gram negative bacilli  is  increasing 
worldwide and is of particular concern in the Intensive Care Unit setting. A 
direct  correlation  has  been  shown  between  resistance  of  Gram  negative 
bacilli  and patient  mortality,  cost  of  patient  care and length of  stay in  the 
hospital. 76   In a study by Kaul et al about the Gram- negative bacterial 
antibiotic susceptibility patterns in IMCU, Christian Medical College, Vellore 
showed that Klebsiella resistance to cefotaxime and ceftazidime ranged from 
25-50% and 14-91%, while E.coli resistance to these antibiotics ranged from 
50-70% and 50-80% respectively.  81    In this study Klebsiella resistance to 
cefotaxime  and  ceftazidime  was  84%  and  E.coli  resistance  to  these 
antibiotics were 43% and 39% respectively.  The resistance of K.pneumoniae 
and E.coli to third generation cephalosporins was higher in this study. 
All  isolates  of  Acinetobacter,  Serratia  and  Enterobactor  were 
sensitive  to  third  generation  cephalosporins.  92%  of  Pseudomonas 
aeruginosa and 94% of Proteus were sensitive to cefotaxime and ceftazidime. 
These findings were similar to the study by Kaul et al from Christian Medical 
College,  Vellore,  who  reported  that  in  Pseudomonas  aeruginosa  and  the 
other  non-fermenting  gram-negative  bacteria  (NFGNB)  Ceftazidime 
resistance  decreased.  Among  Aminoglycosides,  most  of  the  GNB  were 
9
sensitive  to  Amikacin  than  Gentamicin.  Highest  sensitivity  rates  were 
detected for Gatifloxacin than Ciprofloxacin and Ofloxacin among Quinolones. 
These findings were similar to previous studies on antimicrobial  resistance 
among gram-negative bacteria by many authors. 21, 22, 23, 39, 64 
All  Gram  negative  bacilli  isolated  in  this  study  had  a  maximum 
sensitivity pattern to Imipenem and Cefepime. This was similar to the study by 
Lockhart  et  al  about  antimicrobial  resistance among Gram-Negative Bacilli 
causing  infections  in  Intensive  Care  Unit  patients  in  the  United  States 
between 1993 and 2004 76  and Rakshit et al from Mumbai. 13
   Gram-negative bacilli producing ESBL appear to be on the rise in 
Asian countries and pose a serious problem in pulmonary infections. 80   In the 
present study the occurrence of ESBL production among K.pneumoniae and 
E.coli were 82% and 52% respectively. For Klebsiella pneumoniae this finding 
was  higher  than  the  study by  Feizabadi  et  al  (72.8%),  74   Gonlugur  et  al 
(12.2%),  39   Hosoglu et al (68.3%),  72    Asian HAP Working group (0.9% to 
40%) 80   and lower than the study by Verhamme et al (100%), 79 Vitkauskiene 
et al (88.9%), 84  Dey et al (100%).  15     For  E.coli  this  finding  was  higher 
than the study by Gonlugur et al (20.8%), 39  Asian HAP Working group (2.3% 
to 40%) 80   and lower than the study by Hosoglu et al (74.6%), 72   Dey et al 
(100%).  15    
 In  this  study  ESBLs  were  predominantly  present  among  K. 
pneumoniae compared to E. coli. Our findings are similar to that of most of 
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the studies in Europe and USA 38  and the Indian studies by Jain et al  64 and 
Shanmuganathan et al. 65     But studies by Gonlugur et al, 39   Hosoglu et al 72 
and Kumar et al  82    showed higher incidence of ESBLs among E.coli than 
K.pneumoniae. The indiscriminate use of third-generation cephalosporins has 
been proposed as a reason for the rise of ESBL producing strains in India. 80
Among  the  Staphylococcus  aureus  isolates  in  this  study,  the 
occurrence  of  Methicillin  resistance  was  observed  in  54.84%.  This  was 
higher than the study by Leroy et al (33%)  35 and lower than the study by 
Mukhopadhyay et al (59.45%) 18 and Rakshit et al (100%). 13 No Vancomycin 
resistant Staphylococcus aureus was detected in the present study.  
Epidemiological  investigation  of  nosocomial  infections  is  greatly 
facilitated by the use of a precise typing system for the organism involved. 
Our study about the hospital acquired pneumonia in IMCU suggests a high 
prevalence of Klebsiella pneumoniae accounting for 48.2% of total cases. In 
the present study, we have used Klebocin typing and antibiotic sensitivity 
profiles  as  the  typing  methods  for  the  detection  of  source  of  Klebsiella 
infections in our IMCU. Although not comparable to molecular methods in 
discriminatory  power,  antibiogram  and  klebocin  typing  are  simpler  and 
relatively economical method of bacteriological typing. 
In  the  present  study  all  Klebsiella  pneumoniae  isolates  were 
subjected to klebocin typing by spot inoculation method as described by Pal 
et al who done the klebocin typing in their study by spot inoculation method 
9
which was described by Chugh et al with some modifications. Using the spot 
inoculation method, we observed 87.5% typability, whereas   Buffenmyer et 
al, 61    Chibber et al, 60 Malik et al, 43 Aggarwal et al 44   and Pal et al 9    reported 
67%, 72.8%, 83.3%, 73.5% and 71.62% typability respectively. Bauernfeind 
et al ,62   Hall, 59   Israil 46    and  Podschun et al 58  have reported 96.3%, 77%, 
85%  and  96%  typability  respectively  using  streak  and  point  method  for 
klebocin typing. 
Despite the relatively higher typability observed in streak and point 
method,  we  followed  the  spot  inoculation  method.  In  view  of  the  high 
induction of klebocins by mitomycin C, storage stability at -20oC and simplicity 
of the technique, spot inoculation method is more appropriate typing method.9
Nineteen klebocin types were observed in the present study using six 
klebocin producer strains. Pal et al reported that twenty eight klebocin types 
had  been  observed  in  their  study  using  six  klebocin  producer  strains  9 
whereas Malik et al observed four patterns of klebocin types in their study 
with six klebocin producer strains. 43  
 We observed  the  klebocin  types  211  (56.8%),  111  (6.2%),  112 
(5.0%) and 441 (3.7%) were the most common types in our study. According 
to Buffenmyer et al and other previous studies type 444 was considered as 
untypable and these strains accounted for 12.5% of the total strains studied. 
Pal  et  al  reported  types  111  (50%),  211  (5.59%),  312  (3.08%)  and  112 
9
(2.31%) as the commonest klebocin types in their study and 28.37% strains 
could not be typed. 9   
Malik et al found type 312 (43.4%) as the commonest followed by 
type 334 (23.4%), type 112 (16.6%) while remaining 16.6% strains could not 
be typed. 
Chibber  et  al  reported  the  predominant  klebocin  types  as  244 
(14.3%),  313  (13.7%)  and  113  (7.6%).  60    Aggarwal  et  al  observed  the 
commonest klebocin types as 111, 313 and 113. Probably there is variation in  
the prevalence of various klebocin types in different topographical areas and 
institutions. Moreover the set of producer strains used in the present study 
was different from other studies in which they had used a set of producer 
strains standardized by them in their own setups. It  is therefore difficult  to 
compare our typing patterns with other studies.
In the present study, we found that by combination of klebocin types 
and antibiogram of K.pneumoniae isolates, the source of infection could be 
traced in 76.51% cases. In a study on klebocin typing by Chibber et al 60 no 
significant correlation was observed between the source of isolation and the 
klebocin type whereas Pal et al  9    observed when the klebocin typing was 
used in association with antibiogram, in 86.84% cases probable source of 
infection could be detected.
Despite the importance of the findings presented in this study, there 
are some limitations that should be taken into consideration when assessing 
9
our conclusions. First, although for the diagnosis of HAP we did quantitative 
culture of Sputum, BAL and ETA, yet the results from this study need to be 
validated by comparison to gold standards such as histology of lung tissue.
Last, in the present study the reproducibility of the klebocin typing 
was 83%. This was higher than the previous study by Malik et al who showed 
in their study that the reproducibility of the klebocin typing was 73.3%. 43   This 
is  of  major  concern because a useful  and effective  epidemiological  typing 
system should have high reproducibility. In our study the reproducibility may 
be a major problem with  the klebocin typing procedure. This difficulty was 
primarily due to the sensitivity of the test strains to MTCC 432 klebocin and 
was presumably associated with their low titers. This problem was a serious 
shortcoming since, as shown in Table 10 the commonest type in our study 
was 211. This pattern of typing was due to lack of sensitivity of the clinical 
isolates to MTCC 432 klebocin (producer 2). Replacing the producer strain of 
this klebocin with  the strain that yields high-titer  preparations may help in 
achieving  acceptable  reproducibility.  Such  strains  may  be  obtained  by 
screening  Klebsiella  pneumoniae  isolates  for  klebocin  activity  or  testing 
producer strains of other investigators.
In spite of these problems, this study proposed the klebocin typing in 
association with antibiogram as a tool for epidemiological typing of Klebsiella 
pneumoniae  isolates  in  the  laboratories  where  the  facilities  to  perform 
9
genomic  based  molecular  typing  are  not  available.  The  advantages  of 
klebocin typing include (i) the ready availability of required materials in most 
bacteriological  laboratories,  (ii)  the  ability  to  perform the  typing  procedure 
within the usual work day, and (iii) the ability to store the klebocins for future  
use. 
9
REFERENCES
11. Hunter JD. Ventilator Associated Pneumonia. J Postgrad Med 2006; 82: 
172-178. 
12. Hoffken G, Niederman MS. Nosocomial pneumonia; the importance of a 
de-escalating strategy for antibiotic treatment of pneumonia in the ICU. 
Chest 2002; 122:2183-2196.
13. Thomas  M  File,  Jr,  MD.  Hospital-acquired  (nosocomial)  pneumonia  in 
adults. Up To Date. Verson 15.1: September 29, 2006.
14.Kimberly  A.  Davis.  Ventilator-Associated  pneumonia:  A  Review.  J 
Intensive Care Med. 2006; 21:211-226.
15. Robert C Read. Bacterial infections of the lower respiratory tract. Topley & 
Wilson’s. 10th edition, volume-1.2005:640.
16.  Porzecanski  I,  Bowton  DL.  Diagnosis  and  treatment  of  ventilator 
associated pneumonia. Chest 2006; 130: 597-604.
17.Podschun  R,  Ullmann  U.  Klebsiella  spp.  as  Nosocomial  Pathogens: 
Epidemiology, Taxonomy, Typing Methods, and Pathogenicity factors. J. 
Clin. Microbiol. 1998; 11:589-603.
18. Parker  MT.  HAI:  Guidelines  to  laboratory  methods,  WHO  Regional 
Publication European series No.4. P.35, 1978, WHO, Copenhagen.
19.Pal RB, Rebello JS, Banker DD, Jain PK. Klebocin Typing of Klebsiella 
species  isolated  from  nosocomial  infections  in  Intensive  Care  Unit.  J 
Postgrad Med. 1997; 43: 98-101.
20.Mehlhorn  A,  Anderson  J,  Balcer  H.  Review  of  Hospital-Acquired, 
Ventilator-Associated,  and  Health  Care-Associated  Pneumonia  in 
Immunocompetent Adults. US Pharm. 2006; 7: HS-30-36.
21. American  Thoracic  Society;  Infectious  Diseases  Society  of  America. 
Guidelines  for  the  Management  of  Adults  with  Hospital  Acquired, 
Ventilator  Associated  and  Health  Care  Associated  Pneumonia.  Am  J 
Respir Crit Care Med 2005; 171:388-416.
22.Sundaram R, Infirmary V, Glasgow. Nosocomial Pneumonia. Anaesthesia 
UK. Oct.2006.
9
23. Rakshit P, Nagar VS, DeshPande AK. Incidence, Clinical outcome and 
risk stratification of ventilator-Associated Pneumonia- a Prospective cohort 
study. Indian J Crit Care Med 2005; 9: 211-216.
24.Pawar  M,  Mehta  Y,  Trehan  N,  Kulkarni  V.  Ventilator-Associated 
Pneumonia: Incidence, risk factors, outcome, and microbiology. J Cardio 
thorac Vasc. 2003; 17:22-28.
25.Dey  A,  Bairy  I.  Incidence  of  multi  drug-resistant  organisms  causing 
Ventilator-Associated  pneumonia  in  a  tertiary  care  hospital:  A  nine 
month’s prospective study. Ann Thorac Med 2007; 2:52-57.
26.Trivedi TH, Shejale SB, Yeolekar ME. Nosocomial Pneumonia in medical 
Intensive Care Unit. J Assoc Physicians India.2000 Nov; 48(11): 1070-3.
27.Tullu MS, Deshmukh CT, Baveja SM. Bacterial Nosocomial Pneumonia in 
Paediatric Intensive Care Unit. J Postgrad Med 2000; 46:18-22.
28. Mukhopadhyay C, Anudida B, Ayyagari A.  Role of mechanical ventilation 
&  development  of  multi  drug  resistant  organisms  in  hospital  acquired 
pneumonia. Indian J Med Res.2003 Dec; 118:229-235.
29. Merchant M, Karnad DR, Kanbur AA. Incidence of nosocomial pneumonia 
in a Medical Intensive Care Unit and general medical ward patients in a 
public hospital in Bombay, India. J Hosp Infect. 1998 Jun; 39(2):143-8.
30.Cunha BA: Nosocomial Pneumonia. Up To Date 2006, May.
31.Joseph  P.  Lynch  III.  Hospital-Acquired  Pneumonia:  Risk  Factors, 
Microbiology, and Treatment. Chest 2001; 119: 373-384.
32. Muhammad  F.R,  Yasmin  H,  Menon  AR,  et  al.  Pattern  of  Nosocomial 
Infection in two Intensive Care Unit of a tertiary care hospital in Karachi. 
JC PSP 2007; Vol. 17(3): 136-139.
33. Rajasekhar  T,  Anuradha  K,  Suhasini  T,  Lakshmi  V.  The  role  of 
quantitative  cultures  of  non-bronchoscopic  samples  in  Ventilator-
Associated Pneumonia. Indian J Med Microbiol 2006; 24:107-113. 
34. Mehta RM, Niederman MS. Nosocomial Pneumonia in the Intensive Care 
Unit:  Controversies and Dilemmas. J Intensive Care Med.2003;  Vol.18, 
No.4, 175-188.
35. Vincent  JL,  Bihari  DJ,  Suter  PM,  et  al.  The Prevalence of  nosocomial 
infection  in  Intensive  Care  Units  in  Europe:  Results  of  the  European 
Prevalence of Infection in Intensive Care (EPIC) study. EPIC International 
Advisory Committee. JAMA 1995; 274: 639-644.
9
36. Heyland  DK,  Cook DJ,  Griffith  L,  et  al.  The Attributable  Morbidity  and 
Mortality of  Ventilator-Associated Pneumonia in the Critically Ill  Patient. 
Am. J. Respir. Crit. Care Med., 1999 April; 159(4): 1249-1256.
37.Celis R, Torres A, Gatell JM, et al. Nosocomial Pneumonia: A Multivariate 
analysis of risk and prognosis. Chest 1988; 93:318-324.
38. Chastre J, Fagon JY. Ventilator-Associated Pneumonia. Am J Respir Crit 
Care Med 2002; 165:867-903.
39.Chevret S, Hemmer M, Carlet J, Langer M. Incidence and risk factors of 
pneumonia acquired in Intensive Care Units. Results from a multicentre 
prospective  study  on  996  patients.  European  Cooperative  Group  on 
Nosocomial Pneumonia. Intensive Care Med 1993; 19 (5):256-64.
40.Sopena N, Sabira M. Multicentre study of hospital acquired pneumonia in 
non-ICU Patients. Chest 2005 Jan; 127(1): 213-19.
41.John  Roark.  Fighting  Nosocomial  Pneumonia.  Infection  Control  Today. 
05/2003.
42.Alp E, Guven M, Yildiz O, et al. Incidence, risk factors and mortality of  
nosocomial pneumonia in Intensive Care Units: A Prospective study. Ann 
Clin Microbiol Antimicrobials 2004, 3:17.
43. Berba  R,  Alejandria  M,Rosacos  J,  et  al.  Incidence,  Risk  factors  and 
Outcome of Hospital Acquired Pneumonia in Critically Ill  Patients at the 
Philippine General Hospital. Phil J Microbiol Infect Dis1999; 28(2):29-38.
44. Centers for Disease Control and Prevention: Guidelines for Prevention of 
Nosocomial Pneumonia. MMWR Recomm Rep 1997,46(RR-1):1-79.
45.Leroy O, Giradie P, Yazdanpanah Y, et al. Hospital Acquired Pneumonia: 
microbiological data and potential  adequacy of anti  microbial  regimens. 
Eur Respir J 2002; 20: 432-439.
46.Merck Mannual. Hospital-Acquired Pneumonia. Nov 2005.
47.Emori  TG, Gaynes RP. An overview of nosocomial infections, including 
the role of the microbiology laboratory. Clin Microbiol Rev. Oct 1993; 6(4): 
428-442.
48.Jacoby  GA,  Mediros  AA.  More  extended-spectrum  beta-lactamases. 
Antimicrob Agents Chemother 1991; 35:1697-704.
9
49.Gonlugur  U,  Bakici  MZ,  Akkurt  I,  Efeoglu  T.  Antibiotic  susceptibility 
patterns among respiratory isolates of Gram Negative Becilli in a Turkish 
University hospital. BMC Microbiol. 2004; 4:32.
50. Chaudhary U, Aggarwal R. Extended Spectrum β-Lactamases (ESBL) - 
An emerging threat to clinical therapeutics. Indian J Med Microbiol 2004;  
22(2): 75-80.
51. Oncul  O.  Antimicrobial  resistance  pattern  of  Extented  Spectrum  β-
Lactamase producing Klebsiella spp. Indian J Med Res 2007; 125:699-
700.   
52. Winn  WC,  Allen  SD,  Koneman  EW,  et  al.  Taxonomy  of  the 
Enterobacteriaceae. Koneman’s Colour Atlas and Textbook of Diagnostic 
Microbiology. Sixth Edition 2006.
53.Malik  A,  Hesani  SE,  Shahid  M,  Khan  HM,  Ahmad  AJ.  Nosocomial 
Klebsiella infection in neonates in a tertiary care hospital: Protein profile by 
SDS- PAGE and klebocin typing as epidemiological markers. Indian J Med 
Microbiol 2003; 21(2): 82-86.
54.Aggarwal A, Khanna S, Arora U. Characterization, biotyping, antibiogram 
and  klebocin  typing  of   Klebsiella  with  special  reference  to  Klebsiella 
oxytoca. Indian J Med Sci 2003; 57(2): 68-70.
55.Bauernfeind  A,  Petermuller  C,  Schneider  R.  Bacteriocins  as  tools  in 
analysis of Nosocomial Klebsiella pneumoniae infections. J Clin Microbiol 
1981; 14(1):15-19.
56. Israil  AM.  The  significance  of  bacteriocin  typing  of  Klebsiella  strains. 
Zentralbl Bakteriol Mikrobiol Hyg[A]. 1981; 250(1-2): 63-71.
57.Rubin SJ. Klebsiella marker systems. Infect Control. 1985 Feb; 6(2): 59-
63.
58.Aber  RC,  Mackel  DC.  Epidemiological  typing  of  nosocomial 
microorganisms. Am J Med. 1981 Apr; 70(4): 899-905.
59. Edmondson  AS,  Cooke  EM.  The  development  and  assessment  of  a 
bacteriocin typing method for Klebsiella. J Hyg (Lond). 1979 Apr; 82(2):  
207-23.
60.Farmer JJ. Conventional typing methods. J Hosp Infect. 1988 Feb; 11(A): 
309-14.
1
61.Cooke EM, Brayson JC, Edmondson AS, Hall D. An investigation into the 
incidence and sources of Klebsiella infections in hospital patients. J Hyg 
(Lond). 1979 Jun; 82(2): 473-80.
62. Israil AM. Studies concerning the sensitivity of Klebsiella strains to a set of 
Klebsiella bacteriocins. Zentralbl Bakteriol A. 1980; 248(1): 91-8.
63.Podschun  R,  Ullman  U.  Bacteriocin  typing  of  environmental  Klebsiella 
isolates. Zentralbl Hyg Umweltmed. 1993 Nov; 195(1): 22-26.
64. Chhibber S, Vedehra DV. Effect of various inducing agents on bacteriocin 
(klebocin) production by Klebsiella pneumoniae. Folia Microbiol (Praha). 
1987; 32(2): 137-41.
65.Chhibber S, Vedehra DV. Purification and characterization of a bacteriocin 
from Klebsiella pneumoniae 158. J Gen Microbiol. 1986 Apr; 132(4): 1051-
4.
66.James R. Molecular cloning and purification of klebicin B. J Gen Microbiol. 
1988 Sep; 134(9): 2525-33.
67. Pokhil SI, Kosobutskii LA, Ovcharenko BM, et al. The bacteriocin typing of 
Klebsiella pneumoniae strains. Mikrobiol Zh. 1991 Nov-Dec; 53(6): 88-93.
68.Podschun R, Ullman U. Bacteriocin typing of Klebsiella spp. Isolated from 
different sources. Zentralbl Hyg Umweltmed. 1996 Feb; 198(3): 258-64.
69.Hall FA. Bacteriocin typing of Klebsiella spp. J Clin Path. 1971; 24: 712-
716.
70. Chhibber  S,  Goel  A,  Kapoor  N,  Saxena  M,  Vadehra  DV.  Bacteriocin 
(klebocin)  typing  of  clinical  isolates  of  Klebsiella  pneumoniae.  Euro  J 
Epidemiol 1988; 4(1):115-118
71. Buffenmyer CL, Rycheck RR, Yee RB. Bacteriocin (klebocin) sensitivity 
typing of Klebsiella. J Clin Microbiol 1976; 4(3):239-244.
72.Bauerfeind A, Petermuller C. Typing of Enterobacter spp. By bateriocin 
susceptibility and its use in epidemiological analysis.J Clin Microbiol 1984; 
20(1): 70-73.
73. Dykes GA, Hastings JW. Selection and fitness in Bacteriocin- producing 
bacteria. Proc R Soc Lond B1997; 264:683-687.
74. Jain  A,  Mondal  R.  Prevalence  and  antimicrobial  resistance  pattern  of 
extended spectrum β- lactamase producing Klebsiella spp isolated from 
cases of neonatal septicaemia. Indian J Med Res 2007; 125:89-94.
1
75.Shanmuganathan C et al. Learning from an outbreak: ESBL- the essential 
points. Indian J Med Microbiol 2004; 22(4):255-257.
76. Forbes  BA,  Sahm  DF,  Weissfeld  AS.  Bailey  &  Scott’s  Diagnostic 
Microbiology. 12th edi. 2007.
77.Baselski VS, Wunderink RG. Bronchoscopic diagnosis of Pneumonia. Clin 
Microbiol Rev. 1994; 7.4: 533-558.
78. Collee JG, Fraser AG, Marmion BP, Simmons A. Mackie & McCartney 
practical medical microbiology. 14th edi.2006.
79. Tulsi, Chugh D, Siham AG, et al. Colonization and infections of neonates 
by Klebsiella pneumoniae in an intensive care unit. 
80. Jacoby GA,  Han P.  Detection  of  Extended  Spectrum β-Lactamases in 
clinical  isolates  of  Klebsiella  pneumoniae  and  Escherichia  coli.  J  Clin 
Microbiol.1996; 34.4: 908-911.
81. Vercauteren E,  Descheemaeker P,  Ieven M,  Sanders CC, Goosens H. 
Comparison of screening methods for detection of Extended Spectrum β-
Lactamases and their prevalence among blood isolates of Escherichia coli 
and Klebsiella spp. in a Belgian Teaching Hospital.  J Clin Microbiol 1997; 
35(9):2191-2197.
82. Hosoglu  S,  Gundes  S,  Kolayli  F,  et  al.  Extended  spectrum  beta- 
lactamases  in  ceftazidime-  resistant  E.coli  and  Klebsiella  pneumoniae 
isolates in Turkish hospitals. Indian J Med Microbiol 2007; 25:346-50.
83.  Rodrigues C, Joshi P, Jani SH, Alphonse M, Radhakrishnan R, Mehta A.  
Detection of –Lactamases in nosocomial gram negative clinical isolates. 
Indian J Med Microbiol 2004; 22: 247-50.
84. Feizabadi M, Yeganeh MS, Nili F, Mirsalehian AA, Mirafshar SM. PFGE 
analysis of MDR isolates of Klebsiella pneumoniae cultured from patients 
at Tehran hospitals. Euro society of Clin Microbiol Infect Dis. 2008 April;  
p1683.
85.Gupta V. An update on newer β-Lactamases. Indian J Med Res 2007; 
126:417-427.
86. Lockhart  SR,  Abramson  MA,  Beekmann  SE,  Gallagher  G,  Riedel  S, 
Diekema DJ, et al. Antimicrobial resistance among Gram-Negative Bacilli 
1
causing  infections  in  Intensive  Care  Unit  patients  in  the  United  States 
between 1993 and 2004. J Clin Microbiol 2007; 45(10):3352-3359.
87. Aly NY, Al-Mousa HH, Al Asar el SM. Nosocomial infections in a medical-
surgical intensive care unit. Med Princ Pract 2008;17(5):373-7.
88. Gaynes R, Edwards JR. The National Nosocomial Infections surveillance 
System.  Overview  of  nosocomial  infections  caused  by  Gram-Negative 
Bacilli. J Clin Infect Dis 2005; 41:848-54.
89. Verhamme  KMC,  DeCooster  W,  Roo  LD,  Beenhouwer  HD,  Nollet  G, 
Verbeke J, et al. Pathogens in Early-onset and Late-onset Intensive Care 
Unit-  Acquired  Pneumonia.  J  Infect  Control  Hosp  Epidemiol  2007; 
28(4):389-397.
90.Lagamayo EN. Antimicrobial  resistance in major pathogens of hospital- 
acquired  pneumonia  in  Asian  countries.  Am  J  Infect  Control  2008; 
36:S101-8.
91. Kaul S, Brahmadathan KN, Jagannati M, Sundarsanam TD, Pitchamuthu 
K, Abraham OC, John G. One year trends in the gram-negative bacterial 
antibiotic susceptibility patterns in a medical intensive care unit in south 
India. Indian J med Microbiol 2007; 25:230-5.
92. Kumar MS, Lakshmi V, Rajagopalan R. Occurrence of extened spectrum 
beta-  lactamases among Enterobacteriaceae spp.  Isolated  at  a  tertiary 
care institute. Indian J Med Microbiol 2006; 24:208-11.
93. Singhal R, Mohanty S, Sood S, Das B, Kapil A. Profile of bacterial isolates 
from  patients  with  ventilator  associated  pneumonias  in  a  tertiary  care 
hospital in India. Indian J Med Res 2005; 121:63-64.
 
94. Vitkauskiene A et al. Relationship between isolation of extened spectrum 
beta- lactamase producing Klebsiella pneumoniae and course of hospital- 
acquired pneumonia. Medicina 2007; 43(10):778-83.
95.Parasakthi N. Consensus guidelines for the management of infections by 
ESBL- producing bacteria. 2001.
96.Hansotia JB, Agarwal V, Pathak AA, Saoji AM. Extended spectrum beta-
lactamase  mediated  resistance  to  third  generation  cephalosporins  in 
Klebsiella pneumoniae in Nagpur, central India. Indian J Med Res 1997; 
105:158-61.
1
97. Mathur P, Kapil A, Das B, Dhawan B. Prevalence of extended spectrum 
beta-lactamase  producing  Gram  negative  bacteria  in  a  tertiary  care 
hospital. Indian J Med Res 2002; 115:153-7.
98.Grover  SS,  Sharma  M,  Pasha  ST,  Singh  G,  Lal  S.  Antimicrobial 
susceptibility  pattern  and  prevalence  of  extended  spectrum  beta-
lactamase  producing  strains  of  Klebsiella  pneumoniae  from  a  major 
hospital in New Delhi. J Commun Dis 2004; 36:17-26.
99. Datta  P,  Thakur  A,  Mishra  B,  Gupta  V.  Prevalence  of  clinical  strains 
resistant to various beta-lactamases in a tertiary care hospital in India. Jpn 
J Infect Dis 2004; 57:146-9.
1
